header logo image


Page 884«..1020..883884885886..890900..»

Stem Cell Therapy in india – Stem Cell Treatment in Uttar …

February 1st, 2019 8:43 am

Welcome to Stem Cell Consults

Stem Cell Center offers a complete scope of stem cell solutions in India for the treatment of various types of diseases. Our main focus is helping people get back to good health through stem cell treatment. Our organization associated with so many hospitals, medical tourism company and also has our own stem cell research labs in India to provide best quality of stem cells in this advanced stem cell treatment field to provide best quality of treatment for all needed patients al over the world.

We also provide complete stem cell lab set up in all over the world and started some other stem cells labs in other countries via our best and experienced team. We have more than 10 years stem cell research experience and treated more than thousand patients for various diseases and even provide stem cell services to various hospitals in all over the world.

We at stem cell center can proudly say that we give the best stem cells in India. Our years of research, hard work and trials have helped us pioneer and accomplish amazing results when required. Your precious cells are processed utilizing our restrictive technology to guarantee they have the best features required for treatment. Undeveloped cell focus are completely anchored, non-lethal and totally without reactions with an excellent probability of homing and tissue or organ.

We are giving advanced Stem Cell Therapy in India where all other medical treatment fail then this stem cell treatment apply to cure such non-treatable maladies or diseases.

As the main healthcare consultant, stem cell center in India takes care of each and every section of the Medical Tourism Trip to entire India. We guarantee, our patients get the best healthcare service by getting in place, the renowned specialty hospitals, latest stem cell treatments, economical housing and alternatives for the patients.

Our organization is giving best stem cell therapy in India and furthermore has perfection in stem cell treatment in Uttar Pradesh, Delhi NCR and all other all major cities of India for the required patients in all those application which can treat by stem cell therapy. We have stem cells in various forms to improve the better recuperation of patient and refer the best stem cell solutions after the evaluation of patient case study by our experts. Our experts in stem cell cooperate with patients however the total understanding to offer you more peace of mind to develop clear evidence based path. We have highly experts in our team and our experts are strong in research and clinical research from the two perspectives.

Our mission is to offer best stem cell therapy at sensible price not only in India but also throughout the entire world so that every required patients can get best stem cell therapy to enhance his life.

Read the original post:
Stem Cell Therapy in india - Stem Cell Treatment in Uttar ...

Read More...

Stem Cells Definition | Understanding Stem Cells …

January 31st, 2019 2:46 am

*Post also available in: Espaol Romn

Stem cells can multiply (self-renew) and differentiate into every cell within the human body, giving them enormous potential for use in regenerative medicine.

In a developing embryo, stem cells can differentiate into all of the specialized embryonic tissues. In adult humans, stem and progenitor cells act as a repair system for the body, replenishing specialized cells.

Stem cell research has been going on for over 50 years because stem cells have a unique ability to divide and replicate repeatedly. In addition, their unspecialized nature allows them to become a wide variety of tissue types, which gives them enormous potential for use as living cell therapies.

In this article:

Several broad categories of stem cells exist, including:

Originally, all stem cells were classified as either adult stem cells or embryonic stem cells (ESCs). However, a diverse range of stem cell types has since been identified. When iPS cells were discovered in 2006, the research community had a new stem cell type that possessed most of the characteristics of ESCs without the controversy.

To make things simple, apply these definitions to classify stem cells by when they are collected during the human lifecycle:

To understand the functional potential of each stem cell type, scientists like to describe to what degree each stem cell type can differentiate into other cell types.

When assessing the functional potential of stem cells, use the following definitions:

Human embryonic stem cells (hESCs) are totipotent cells that are derived from embryos that have been createdin vitroat fertility clinics with informed donor consent. Embryonic stem cells are typically collected shortly after fertilization (within 4-5 days). At 5-6 days post-fertilization, embryonic stem cells begin to specialize, at which point they become pluripotent or multipotent cells.

Pluripotent and multipotent stem cells have a more limited differentiation capacity than totipotent stem cells.For example, multipotent blood stem cells can differentiate into red cells, white cells, and platelets in the blood, but they cannot become any cell type.

The precisepointat which a stem cell switches from a totipotent stem cell to a pluripotent or multipotent stem cell is often unclear. Furthermore, iPS cell technology allows us to reverse mature cell types back into a totipotent state. iPS cells are totipotent, so stem cells can now be collected at any point in the human lifecycle.

Today, most clinics that offer stem cell treatments administer mesenchymal stem cells (MSCs), which they source from fat tissue orbone marrow. Mesenchymal stem cells are a type of multipotent stem cell that is being explored for use in the orthopedic repair, pain management, arthritis, asthma, and many other applications. MSCs tend to exert effects on other cells and tissues within the human body, which is called paracrine signaling.

Although risks will exist whenever cell therapies are administered to humans, a large body of scientific evidence suggests that MSCs can be safe for patient use when properly administered and monitored.There is an additional layer of safety that occurs when cells are multipotent (limited in their differentiation capacity). Often, it is safer for them to be self-derived (autologous), rather than from someone else (allogeneic).

Another stem cell type that is commonly used is the hematopoietic stem cell (HSC). HSC transplantation has been used for decades as a means of rebuilding the immune system after a patient undergoes radiation or chemotherapy.

There are many companies working to introduce legitimate stem cell therapies into clinical practice. Unfortunately, there are also unregulated stem cell groups that are offering unverified and unsafe stem cell therapies to patients.

One of the risks of totipotent stem cells (embryonic stem cells and iPS cells) is that they have the potential to produce uncontrolled proliferation. The biggest concern surrounding the clinical application of these cells is their tendency to form tumors. Pluripotent and multipotent stem cells have a lower risk of producing tumor formation, but can potentially create growth of the wrong tissue type for a given location within the human body. Additionally, iPS cells are artificially manipulated in a laboratory process, so there is the possibility that the cells can act in unexpected ways.

Because many of these risks can be mitigated and monitored, stem cells are currently being investigated in hundreds of clinical trials worldwide. The majority of these clinical trials involve the use of mesenchymal stem cells (MSCs) and hematopoietic stem cells (HSCs). Approximately three-quarters of these stem cell trials worldwide are registered at ClinicalTrials.gov. You can screen that public database to search for trials by condition, disease, location, or sponsor. Additional trials can be found on a country-by-country basis.

To make things more complex, the U.S. FDA regulates stem cell treatments as two different types, commonly called 361 and 351 products:

To share your own knowledge or experience with stem cells, comment below.

Up Next: Advanced Dental Care: Guide To Dental Stem Cell Companies

If you need this information on the go, download your free PDF Fact Sheet below.

Stem Cells Definition | Understanding Stem Cells

Read this article:
Stem Cells Definition | Understanding Stem Cells ...

Read More...

Adult stem cell – Wikipedia

January 31st, 2019 2:46 am

Adult stem cells are undifferentiated cells, found throughout the body after development, that multiply by cell division to replenish dying cells and regenerate damaged tissues. Also known as somatic stem cells (from Greek , meaning of the body), they can be found in juvenile as well as adult animals and humans, unlike embryonic stem cells.

Scientific interest in adult stem cells is centered on their ability to divide or self-renew indefinitely, and generate all the cell types of the organ from which they originate, potentially regenerating the entire organ from a few cells.[1] Unlike for embryonic stem cells, the use of human adult stem cells in research and therapy is not considered to be controversial, as they are derived from adult tissue samples rather than human embryos designated for scientific research. They have mainly been studied in humans and model organisms such as mice and rats.

A stem cell possesses two properties:

Hematopoietic stem cells are found in the bone marrow and umbilical cord blood and give rise to all the blood cell types.[3]

Mammary stem cells provide the source of cells for growth of the mammary gland during puberty and gestation and play an important role in carcinogenesis of the breast.[4] Mammary stem cells have been isolated from human and mouse tissue as well as from cell lines derived from the mammary gland. Single such cells can give rise to both the luminal and myoepithelial cell types of the gland, and have been shown to have the ability to regenerate the entire organ in mice.[4]

Intestinal stem cells divide continuously throughout life and use a complex genetic program to produce the cells lining the surface of the small and large intestines.[5] Intestinal stem cells reside near the base of the stem cell niche, called the crypts of Lieberkuhn. Intestinal stem cells are probably the source of most cancers of the small intestine and colon.[6]

Mesenchymal stem cells (MSCs) are of stromal origin and may differentiate into a variety of tissues. MSCs have been isolated from placenta, adipose tissue, lung, bone marrow and blood, Wharton's jelly from the umbilical cord,[7] and teeth (perivascular niche of dental pulp and periodontal ligament).[8] MSCs are attractive for clinical therapy due to their ability to differentiate, provide trophic support, and modulate innate immune response.[7] These cells have the ability to differentiate into various cell types such as osteoblasts, chondroblasts, adipocytes, neuroectodermal cells, and hepatocytes.[9] Bioactive mediators that favor local cell growth are also secreted by MSCs. Anti-inflammatory effects on the local microenvironment, which promote tissue healing, are also observed. The inflammatory response can be modulated by adipose-derived regenerative cells (ADRC) including mesenchymal stem cells and regulatory T-lymphocytes. The mesenchymal stem cells thus alter the outcome of the immune response by changing the cytokine secretion of dendritic and T-cell subsets. This results in a shift from a pro-inflammatory environment to an anti-inflammatory or tolerant cell environment.[10][11]

Endothelial stem cells are one of the three types of multipotent stem cells found in the bone marrow. They are a rare and controversial group with the ability to differentiate into endothelial cells, the cells that line blood vessels.

The existence of stem cells in the adult brain has been postulated following the discovery that the process of neurogenesis, the birth of new neurons, continues into adulthood in rats.[12] The presence of stem cells in the mature primate brain was first reported in 1967.[13] It has since been shown that new neurons are generated in adult mice, songbirds and primates, including humans. Normally, adult neurogenesis is restricted to two areas of the brain the subventricular zone, which lines the lateral ventricles, and the dentate gyrus of the hippocampal formation.[14] Although the generation of new neurons in the hippocampus is well established, the presence of true self-renewing stem cells there has been debated.[15] Under certain circumstances, such as following tissue damage in ischemia, neurogenesis can be induced in other brain regions, including the neocortex.

Neural stem cells are commonly cultured in vitro as so called neurospheres floating heterogeneous aggregates of cells, containing a large proportion of stem cells.[16] They can be propagated for extended periods of time and differentiated into both neuronal and glia cells, and therefore behave as stem cells. However, some recent studies suggest that this behaviour is induced by the culture conditions in progenitor cells, the progeny of stem cell division that normally undergo a strictly limited number of replication cycles in vivo.[17] Furthermore, neurosphere-derived cells do not behave as stem cells when transplanted back into the brain.[18]

Neural stem cells share many properties with haematopoietic stem cells (HSCs). Remarkably, when injected into the blood, neurosphere-derived cells differentiate into various cell types of the immune system.[19]

Olfactory adult stem cells have been successfully harvested from the human olfactory mucosa cells, which are found in the lining of the nose and are involved in the sense of smell.[20] If they are given the right chemical environment these cells have the same ability as embryonic stem cells to develop into many different cell types. Olfactory stem cells hold the potential for therapeutic applications and, in contrast to neural stem cells, can be harvested with ease without harm to the patient. This means they can be easily obtained from all individuals, including older patients who might be most in need of stem cell therapies.

Hair follicles contain two types of stem cells, one of which appears to represent a remnant of the stem cells of the embryonic neural crest. Similar cells have been found in the gastrointestinal tract, sciatic nerve, cardiac outflow tract and spinal and sympathetic ganglia. These cells can generate neurons, Schwann cells, myofibroblast, chondrocytes and melanocytes.[21][22]

Multipotent stem cells with a claimed equivalency to embryonic stem cells have been derived from spermatogonial progenitor cells found in the testicles of laboratory mice by scientists in Germany[23][24][25] and the United States,[26][27][28][29] and, a year later, researchers from Germany and the United Kingdom confirmed the same capability using cells from the testicles of humans.[30] The extracted stem cells are known as human adult germline stem cells (GSCs)[31]

Multipotent stem cells have also been derived from germ cells found in human testicles.[32]

To ensure self-renewal, stem cells undergo two types of cell division (see Stem cell division and differentiation diagram). Symmetric division gives rise to two identical daughter cells, both endowed with stem cell properties, whereas asymmetric division produces only one stem cell and a progenitor cell with limited self-renewal potential. Progenitors can go through several rounds of cell division before finally differentiating into a mature cell. It is believed that the molecular distinction between symmetric and asymmetric divisions lies in differential segregation of cell membrane proteins (such as receptors) between the daughter cells.

Discoveries in recent years have suggested that adult stem cells might have the ability to differentiate into cell types from different germ layers. For instance, neural stem cells from the brain, which are derived from ectoderm, can differentiate into ectoderm, mesoderm, and endoderm.[33] Stem cells from the bone marrow, which is derived from mesoderm, can differentiate into liver, lung, GI tract and skin, which are derived from endoderm and mesoderm.[34] This phenomenon is referred to as stem cell transdifferentiation or plasticity. It can be induced by modifying the growth medium when stem cells are cultured in vitro or transplanting them to an organ of the body different from the one they were originally isolated from. There is yet no consensus among biologists on the prevalence and physiological and therapeutic relevance of stem cell plasticity. More recent findings suggest that pluripotent stem cells may reside in blood and adult tissues in a dormant state.[35] These cells are referred to as "Blastomere Like Stem Cells"[36] and "very small embryonic like" "VSEL" stem cells, and display pluripotency in vitro.[35] As BLSC's and VSEL cells are present in virtually all adult tissues, including lung, brain, kidneys, muscles, and pancreas[37] Co-purification of BLSC's and VSEL cells with other populations of adult stem cells may explain the apparent pluripotency of adult stem cell populations. However, recent studies have shown that both human and murine VSEL cells lack stem cell characteristics and are not pluripotent.[38][39][40][41]

Stem cell function becomes impaired with age, and this contributes to progressive deterioration of tissue maintenance and repair.[42] A likely important cause of increasing stem cell dysfunction is age-dependent accumulation of DNA damage in both stem cells and the cells that comprise the stem cell environment.[42] (See also DNA damage theory of aging.)

Adult stem cells can, however, be artificially reverted to a state where they behave like embryonic stem cells (including the associated DNA repair mechanisms). This was done with mice as early as 2006[43] with future prospects to slow down human aging substantially. Such cells are one of the various classes of induced stem cells.

Adult stem cell research has been focused on uncovering the general molecular mechanisms that control their self-renewal and differentiation.

Adult stem cell treatments have been used for many years to successfully treat leukemia and related bone/blood cancers utilizing bone marrow transplants.[47] The use of adult stem cells in research and therapy is not considered as controversial as the use of embryonic stem cells, because the production of adult stem cells does not require the destruction of an embryo.

Early regenerative applications of adult stem cells has focused on intravenous delivery of blood progenitors known as Hematopetic Stem Cells (HSC's). CD34+ hematopoietic Stem Cells have been clinically applied to treat various diseases including spinal cord injury,[48] liver cirrhosis [49] and Peripheral Vascular disease.[50] Research has shown that CD34+ hematopoietic Stem Cells are relatively more numerous in men than in women of reproductive age group among spinal cord Injury victims.[51] Other early commercial applications have focused on Mesenchymal Stem Cells (MSCs). For both cell lines, direct injection or placement of cells into a site in need of repair may be the preferred method of treatment, as vascular delivery suffers from a "pulmonary first pass effect" where intravenous injected cells are sequestered in the lungs.[52] Clinical case reports in orthopedic applications have been published. Wakitani has published a small case series of nine defects in five knees involving surgical transplantation of mesenchymal stem cells with coverage of the treated chondral defects.[53] Centeno et al. have reported high field MRI evidence of increased cartilage and meniscus volume in individual human clinical subjects as well as a large n=227 safety study.[54][55][56][57] Many other stem cell based treatments are operating outside the US, with much controversy being reported regarding these treatments as some feel more regulation is needed as clinics tend to exaggerate claims of success and minimize or omit risks.[58]

The therapeutic potential of adult stem cells is the focus of much scientific research, due to their ability to be harvested from the parent body that is females during the delivery.[59][60][61] In common with embryonic stem cells, adult stem cells have the ability to differentiate into more than one cell type, but unlike the former they are often restricted to certain types or "lineages". The ability of a differentiated stem cell of one lineage to produce cells of a different lineage is called transdifferentiation. Some types of adult stem cells are more capable of transdifferentiation than others, but for many there is no evidence that such a transformation is possible. Consequently, adult stem therapies require a stem cell source of the specific lineage needed, and harvesting and/or culturing them up to the numbers required is a challenge.[62][63] Additionally, cues from the immediate environment (including how stiff or porous the surrounding structure/extracellular matrix is) can alter or enhance the fate and differentiation of the stem cells.[64]

Pluripotent stem cells, i.e. cells that can give rise to any fetal or adult cell type, can be found in a number of tissues, including umbilical cord blood.[65] Using genetic reprogramming, pluripotent stem cells equivalent to embryonic stem cells have been derived from human adult skin tissue.[66][67][68][69][70] Other adult stem cells are multipotent, meaning they are restricted in the types of cell they can become, and are generally referred to by their tissue origin (such as mesenchymal stem cell, adipose-derived stem cell, endothelial stem cell, etc.).[71][72] A great deal of adult stem cell research has focused on investigating their capacity to divide or self-renew indefinitely, and their potential for differentiation.[73] In mice, pluripotent stem cells can be directly generated from adult fibroblast cultures.[74]

In recent years, acceptance of the concept of adult stem cells has increased. There is now a hypothesis that stem cells reside in many adult tissues and that these unique reservoirs of cells not only are responsible for the normal reparative and regenerative processes but are also considered to be a prime target for genetic and epigenetic changes, culminating in many abnormal conditions including cancer.[75][76] (See cancer stem cell for more details.)

Adult stem cells express transporters of the ATP-binding cassette family that actively pump a diversity of organic molecules out of the cell.[77] Many pharmaceuticals are exported by these transporters conferring multidrug resistance onto the cell. This complicates the design of drugs, for instance neural stem cell targeted therapies for the treatment of clinical depression.

Read more:
Adult stem cell - Wikipedia

Read More...

Nanomedicine | medicine | Britannica.com

January 31st, 2019 2:45 am

Nanomedicine, branch of medicine that seeks to apply nanotechnologythat is, the manipulation and manufacture of materials and devices that are smaller than 1 nanometre [0.0000001 cm] in sizeto the prevention of disease and to imaging, diagnosis, monitoring, treatment, repair, and regeneration of biological systems.

Although nanomedicine remains in its early stages, a number of nanomedical applications have been developed. Research thus far has focused on the development of biosensors to aid in diagnostics and vehicles to administer vaccines, medications, and genetic therapy, including the development of nanocapsules to aid in cancer treatment.

An offshoot of nanotechnology, nanomedicine is an emerging field and had garnered interest as a site for global research and development, which gives the field academic and commercial legitimacy. Funding for nanomedicine research comes both from public and private sources, and the leading investors are the United States, the United Kingdom, Germany, and Japan. In terms of the volume of nanomedicine research, these countries are joined by China, France, India, Brazil, Russia, and India.

Working at the molecular-size scale, nanomedicine is animated with promises of the seamless integration of biology and technology, the eradication of disease through personalized medicine, targeted drug delivery, regenerative medicine, as well as nanomachinery that can substitute portions of cells. Although many of these visions may not come to fruition, some nanomedicine applications have become reality, with the potential to radically transform the practice of medicine, as well as current understandings of the health, disease, and biologyissues that are of vital importance for contemporary societies. The fields global market share totalled some $78 billion dollars in 2012, driven by technological advancements. By the end of the decade, the market is expected to grow to nearly $200 billion.

Nanomedicine derives much of its rhetorical, technological, and scientific strength from the scale on which it operates (1 to 100 nanometers), the size of molecules and biochemical functions. The term nanomedicine emerged in 1999, the year when American scientist Robert A. Freitas Jr. published Nanomedicine: Basic Capabilities, the first of two volumes he dedicated to the subject.

Extending American scientist K. Eric Drexlers vision of molecular assemblers with respect to nanotechnology, nanomedicine was depicted as facilitating the creation of nanobot devices (nanoscale-sized automatons) that would navigate the human body searching for and clearing disease. Although much of this compelling imagery still remains unrealized, it underscores the underlying vision of doctors being able to search and destroy diseased cells, or of nanomachines that substitute biological parts, which still drives portrayals of the field. Such illustrations remain integral to the field, being used by scientists, funding agencies, and the media alike.

Attesting to the fields actuality are numerous dedicated scientific and industry-oriented conferences, peer-reviewed scientific journals, professional societies, and a growing number of companies. However, nanomedicines identity, scope, and goals are a matter of controversy. In 2006, for instance, the prestigious journal Nature Materials discussed the ongoing struggle of policy makers to understand if nanomedicine is a rhetorical issue or a solution to a real problem. This ambivalence is reflected in the numerous definitions of nanomedicine that can be found in scientific literature, that range from complicated drugs to the above mentioned nanobots. Despite the lack of a shared definition, there is a general agreement that nanomedicine entails the application of nanotechnology in medicine and that it will profoundly impact medical practice.

A further topic of debate is nanomedicines genealogy, in particular its connections to molecular medicine and nanotechnology. The case of nanotechnology is exemplary: on one hand, its potentialin terms of science but also in regard to funding and recognitionis often mobilized by nanomedicine proponents; on the other, there is an attempt to distance nanomedicine from nanotechnology, for fear of being damaged by the perceived hype that surrounds it. The push is then for nanomedicine to emerge not as a subdiscipline of nanotechnology but as a parallel field.

Although nanomedicine research and development is actively pursued in numerous countries, the United States, the EU (particularly Germany), and Japan have made significant contributions from the fields outset. This is reflected both in the number of articles published and in that of patents filed, both of which have grown exponentially since 2004. By 2012, however, nanomedicine research in China grew with respect to publications in the field, and the country ranked second only to the United States in the number of research articles published.

In 2004, two U.S. funding agenciesthe National Institutes of Health and the National Cancer Instituteidentified nanomedicine as a priority research area allocating $144 million and $80 million, respectively, to its study. In the EU meanwhile, public granting institutions did not formally recognize nanomedicine as a field, providing instead funding for research that falls under the headers of nanotechnology and health. Such lack of coordination had been the target of critiques by the European Science Foundation (ESF), warning that it would result in lost medical benefits. In spite of this, the EU ranked first in number of nanomedicine articles published and in 2007 the Seventh Framework Programme (FP7) allocated 250 million to nanomedicine research. Such work has also been heavily funded by the private sector. A study led by the European Science and Technology Observatory found that over 200 European companies were researching and developing nanomedicine applications, many of which were coordinating their efforts.

Much of nanomedicine research is application oriented, emphasizing methods to transfer it from the laboratory to the bedside. In 2005 the ESF pointed to four main subfields in nanomedicine research: analytical tools and nanoimaging, nanomaterials and nanodevices, novel therapeutics and drug delivery systems, and clinical, regulatory, and toxicological issues. Research in analytical tools and nanoimaging seeks to develop noninvasive, reliable, cheap, and highly sensitive tools for in vivo diagnosis and visualization. The ultimate goal is to create fully functional mobile sensors that can be remotely controlled to conduct in vivo, real-time analysis. Research on nanomaterials and nanodevices aims to improve the biocompatibility and mechanical properties of biomaterials used in medicine, so as to create safer implants, substitute damaged cell parts, or stimulate cell growth for tissue engineering and regeneration, to name a few. Work in novel therapeutics and drug delivery systems strives to develop and design nanoparticles and nanostructures that are noninvasive and can target specific diseases, as well as cross biological barriers. Allied with very precise means for diagnosis, these drug delivery systems would enable equally precise site-specific therapeutics and fewer side effects. The area of drug delivery accounts for a large portion of nanomedicines scientific publications.

Finally, the subfield of clinical, regulatory, and toxicological issues lumps together research that examines the field as a whole. Questions of safety and toxicology are prevalent, an issue that is all the more important given that nanomedicine entails introducing newly engineered nanoscale particles, materials, and devices into the human body. Regulatory issues revolve around the management of this newness, with some defending the need for new regulation, and others the ability of systems to deal with it. This subfield should also include other research by social scientists and humanists, namely on the ethics of nanomedicine.

Combined, these subfields build a case for preventive medicine and personalized medicine. Building upon genomics, personalized medicine envisions the possibility of individually tailored diagnostics and therapeutics. Preventive medicine takes this notion further, conjuring the possibility of treating a disease before it manifests itself. If realized, such shifts would have radical impacts on understandings of health, embodiment, and personhood. Questions remain concerning the cost and accessibility of nanomedicine and also about the consequences of diagnostics based on risk propensity or that lack a cure.

More:
Nanomedicine | medicine | Britannica.com

Read More...

Precision Medicine Executive Summit: Cutting-edge Insights

January 31st, 2019 2:45 am

Our 2018 conference featured keynote address by JeffreyR. Balser, M.D., Ph.D.,President and CEO, Vanderbilt University Medical Centerand Dean of the Vanderbilt University School of Medicine,one of the most progressive and innovative health systems in the country.

CEOs and administrators at the nations leading health networks and hospitals recognize this truth: precision medicine is poised to transform clinical care in ways that experts say will be highly disruptive to health networks, particularly those that are slow to respond to thisimportant trend.

That makes it imperative for CEOs and senior administrators at health networks everywhere to get answers to these two questions:1) How is precision medicine now changing clinical care today, including specific programs already used by networks and physicians to improve patient outcomes, reduce costs, and open the door to new sourcesof revenue?2) What precision medicine strategy is best for my health network and its hospitals?

Attendees will find answers to both questions at our Precision Medicine Institute Symposium 2019, taking place Thursday and Friday, May 2-3 at the Sheraton Hotel in New Orleans, LA.

During this intensive 1 1/2 day conference, the nations first movers and early adopters will discuss their first programs to infuse precision medicine into specific areas of clinical care. On topics ranging from spectacular success in oncology and cancer care, offering patients access to pharmacogenetic testing in primary care settings, and more, youll hear sessions and speakers with up-to-the minute insights so needed to develop the right precision medicine strategy for todays health networks.

Precision medicine is becoming real. It's no longer something for an egghead institution to dabble in. It can be used as a strategic advantage in terms of delivering efficient care, competing with other health systems, ways of making sure that patients are having as much risk mitigated as possible. It's an ideal opportunity to really fine-tune a health system. a really engaged audience and the type you don't normally get to speak with. Having leadership at health systems, at health companies, at other types of health enterprises, you have a different type of thinking. The networking is strong.

Howard McCloud, MDMedical Director, Personalized MedicineMoffitt Cancer Center, Tampa, FL

See All Testimonials

See the original post:
Precision Medicine Executive Summit: Cutting-edge Insights

Read More...

Where Do Stem Cells Come From? | Basics Of Stem Cell …

January 31st, 2019 2:44 am

Where do stem cells come from? Learn the basics of master cells to better understand their therapeutic potential.

In this article:

Where do stem cells come from? You have probably heard of thewonders of stem cell therapy. Not only do stem cells make research for future scientific breakthroughs possible, but they also provide the basis for many medical treatments today. So, where exactly are they from, and how are they different from regular cells? The answer depends on the types of stem cells in question.

There are two main types of stem cells adult and embryonic:

Beyond the two broader categories, there are sub-categories. Each has its own characteristics. For researchers, the different types of stem cells serve specific purposes.

Many tissues throughout the adult human body contain stem cells. Scientists previously believed adult stem cells to be inferior to human embryonic stem cells for therapeutic purposes. Theydid not believe adult stem cells to be as versatile as embryonic stem cells (ESCs), because they are not capable of becoming all 200 cell types within the human body.

While this theoryhas notbeen entirely disproved, encouraging evidence suggests that adult stem cells can develop into a variety of new types of cells. They can also affect repair through other mechanisms.

In August 2017, the number of stem cell publications registered in PubMed, a government database, surpassed 300,000. Stem cells are also being explored in over 4,600 cell therapy clinical trials worldwide. Some of the earliest forms of adult stem cell use include bone marrow and umbilical cord blood transplantation.

It should be noted that while the term adult stem cell is used for this type of cell, it is not descriptive of age, because adult stem cells can come from children. The term simply helps to differentiate stem cells derived from living humans as opposed to embryonic stem cells.

Embryonic stem cells are controversial because they are made from embryos that are created but not used by fertility clinics.

Because adult stem cells are somewhat limited in the cell types they can become, scientists developed a way to genetically reprogram cells into what is called an inducedpluripotent stem cell or iPS cell. In creating inducedpluripotent stem cells, researchers hope to blend the usefulness of adult stem cells with the promise of embryonic stem cells.

Both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) are known as pluripotent stem cells.

Pluripotent stem cells are a type of cell that has the capacity to divide indefinitely and create any cell found within the three germ layers of an organism: ectoderm (cells forming the skin and nervous system), endoderm (cells forming pancreas, liver, endocrine gland, and gastrointestinal and respiratory tracts), and mesoderm (cells forming connective tissues, and other related tissues, muscles, bones, most of the circulatory system, and cartilage).

Embryonic stem cells can grow into a much wider range of cell types, but they also carry the risk of immune system rejection in patients. In contrast, adult stem cells are more plentiful, easier to harvest, and less controversial.

Embryonic stem cells come from embryos harvested shortly after fertilization (within 4-5 days). These cells are made when the blastocysts inner cell mass is transferred into a culture medium, allowing them to develop.

At 5-6 days post-fertilization, the cells within the embryo start to specialize. At this time, they no longer are able to become all of the cell types within the human body. They are no longer pluripotent.

Because they are pluripotent, embryonic stem cells can be used to generate healthy cells for disease patients. For example, they can be grown into heart cells known as cardiomyocytes. These cells may have the potential to be injected into an ailing patients heart.

Harvesting stem cells from embryos is controversial, so there are guidelines created by the National Institutes of Health (NIH) that allow the public to understand what practices are not allowed.

Scientists can harvest perinatal stem cells from a variety of tissues, but the most common sources include:

The umbilical cord attaches a mother to her fetus. It is removed after birth and is a valuable source of stem cells. The blood it contains is rich in hematopoietic stem cells (HSC). It also contains smaller quantities of another cell type known as mesenchymal stem cells (MSCs).

The placenta is a large organ that acts as a connector between the mother and the fetus. Both placental blood and tissue are also rich in stem cells.

Finally, there is amniotic fluid surrounding a baby while it is in utero. It can be harvested if a pregnant woman needs a specialized kind of test known as amniocentesis. Both amniotic fluid and tissue contain stem cells, too.

Adult stem cells are usually harvested in one of three ways:

The blood draw, known as peripheral blood stem cell donation, extracts the stem cells directly from a donors bloodstream. The bone marrow stem cells come from deep within a bone often a flat bone such as the hip. Tissue fat is extracted from a fatty area, such as the waist.

Embryonic donations are harvested from fertilized human eggs that are less than five days old. The embryos are not grown within a mothers or surrogates womb, but instead, are multiplied in a laboratory. The embryos selected for harvesting stem cell are created within invitro fertilization clinics but are not selected for implantation.

Amniotic stem cells can be harvested at the same time that doctors use a needle to withdraw amniotic fluid during a pregnant womans amniocentesis. The same fluid, after being tested to ensure the babys health, can also be used to extract stem cells.

As mentioned, there is another source for stem cells the umbilical cord. Blood cells from the umbilical cord can be harvested after a babys birth. Cells can also be extracted from the postpartumhuman placenta, which is typically discarded as medical waste following childbirth.

The umbilical cord and the placenta are non-invasive sources of perinatal stem cells.

People who donate stem cells through the peripheral blood stem cell donor procedure report it to be a relativelypainless procedure. Similar to giving blood, the procedure takes about four hours. At a clinic or hospital, an able medical practitioner draws the blood from the donors vein in one of his arms using a needle injection. The technician sends the drawn blood into a machine, which extracts the stem cells. The blood is then returned to the donors body via a needle injected into the other arm. Some patients experience cramping or dizziness, but overall, its considered a painless procedure.

If a blood stem cell donor has a problem with his or her veins, a catheter may be injected in the neck or chest. The donor receives local anesthesia when a catheter-involved donation occurs.

During a bone marrow stem cell donor procedure, the donor is put under heavy sedation in an operating room. The hip is often the site chosen to harvest the bone marrow. More of the desired red marrow is found in flat bones, such as those in the pelvic region. The procedure takes up to two hours, with several extractions made while the patient is sedated. Although the procedure is painless due to sedation, recovery can take a couple of weeks.

Bone marrow stem cell donation takes a toll on the donorbecause it involves the extraction of up to 10 percent of the donors marrow. During the recovery period, the donors body gradually replenishes the marrow. Until that happens, the donor may feel fatigued and sore.

Some clinics offer regenerative and cosmetic therapies using the patients own stem cells derived from the fat tissue located on the sides of the waistline. Considered a simple procedure, clinics do this for therapeutic reasons or as a donation for research.

Stem cells differ from the trillions of other cells in your body. In fact, stem cells make up only a small fraction of the total cells in your body. Some people have a higher percentage of stem cells than others. But, stem cells are special because they are the mothers from which specialized cells grew and developed within us. When these cells divide, they become daughters. Some daughter cells simply self-replicate, while others form new kinds of cells altogether. This is the main way stem cells differ from other body cells they are the only ones capable of generating new cells.

The ways in which stem cells can directly treat patients grow each year. Regenerative medicine now relies heavily on stem cell applications. This type of treatment replaces diseased cells with new, healthy ones generated through donor stem cells. The donor can be another person or the patient themselves.

Sometimes, stem cells also exert therapeutic effects by traveling through the bloodstream to sites that need repair or by impacting their micro-environment through signaling mechanisms.

Some types of adult stem cells, like mesenchymal stem cells (MSCs), are well-known for exerting anti-inflammatory and anti-scarring effects. MSCs can also positively impact the immune system.

Conditions and diseases which stem cell regeneration therapy may help include Alzheimers disease, Parkinsons disease, and multiple sclerosis (MS). Heart disease, certain types of cancer, and stroke victims may also benefit in the future. Stem cell transplant promises advances in treatment for diabetes, spinal cord injury, severe burns, and osteoarthritis.

Researchers also utilize stem cells to test new drugs. In this case, an unhealthy tissue replicates into a larger sample. This method enables researchers to test various therapies on a diseased sample, rather than on an ailing patient.

Stem cell research also allows scientists to study how both healthy and diseased tissue grows and mutates under various conditions. They do this by harvesting stem cells from the heart, bones, and other body areas and studying them under intensive laboratory conditions. In this way, they get a better understanding of the human body, whether healthy or sick.

With the following stem cell transplant benefits, its not surprising people would like to try the therapy as another treatment option.

Physicians harvest stem cell from either the patient or a donor. For an autologous transplant, there is no risk of transferring any disease from another person. For an allogeneic transplant, the donor is meticulously screened before the therapy to make sure they are compatible with the patient and have healthy sources of stem cells.

One common and serious problem of transplants is the risk of rejecting the transplanted organs, tissues, stem cells, and others. With autologous stem cell therapy, the risk is avoided primarily because it comes from the same person.

Because stem cell transplants are typically done through infusion or injection, the complex and complicated surgical procedure is avoided. Theres no risk of accidental cuts and scarring post-surgery.

Recovery time from surgeries and other types of treatments is usually time-consuming. With stem cell therapy, it could only take about 3 months or less to get the patient back to their normal state.

As the number of stem cell treatments dramatically grew over the years, its survival rate also increased. A study published in the Journal of Clinical Oncology showed there was a significant increase in survival rate over 12 years among participants of the study. The study analyzed results from over 38,000 stem cell transplants on patients with blood cancers and other health conditions.

One hundred days following transplant, the researchers observed an improvement in the survival rate of patients with myeloid leukemia. The significant improvements we saw across all patient and disease populations should offer patients hope and, among physicians, reinforce the role of blood stem cell transplants as a curative option for life-threatening blood cancers and other diseases.

With the information above, people now have a better understanding of the answer to the question Where do stem cells come from? Stem cells are a broad topic to comprehend, and its better to go back to its basics to learn its mechanisms. This way, a person can have a piece of detailed knowledge about these master cells from a scientific perspective.

If you found this blog valuable, subscribe to BioInformants stem cell industry updates.

As the first and only market research firm to specialize in the stem cell industry, BioInformant research is cited by The Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Bringing you breaking news on an ongoing basis, we encourage you to join more than half a million loyal readers, including physicians, scientists, executives, and investors.

What do you understand aboutthe basics of stem cells? Share your thoughts in the comments section below.

Up Next:Top 5 TED Talks About Stem Cells

Where Do Stem Cells Come From? | Basics Of Stem Cell Therapy

Continue reading here:
Where Do Stem Cells Come From? | Basics Of Stem Cell ...

Read More...

Types of Stem Cells A Closer Look at Stem Cells

January 31st, 2019 2:44 am

Tissue-specific stem cells

Tissue-specific stem cells (also referred to assomaticoradultstem cells) are more specialized than embryonic stem cells. Typically, these stem cells can generate different cell types for the specific tissue or organ in which they live.

For example, blood-forming (orhematopoietic) stem cells in the bone marrow can give rise to red blood cells, white blood cells and platelets. However, blood-forming stem cells dont generate liver or lung or brain cells, and stem cells in other tissues and organs dont generate red or white blood cells or platelets.

Some tissues and organs within your body contain small caches of tissue-specific stem cells whose job it is to replace cells from that tissue that are lost in normal day-to-day living or in injury, such as those in your skin, blood, and the lining of your gut.

Tissue-specific stem cells can be difficult to find in the human body, and they dont seem to self-renew in culture as easily as embryonic stem cells do. However, study of these cells has increased our general knowledge about normal development, what changes in aging, and what happens with injury and disease.

Here is the original post:
Types of Stem Cells A Closer Look at Stem Cells

Read More...

Stem Cell | Regenerative medicine | 2019 | Conference …

January 29th, 2019 4:44 pm

Responsibility

The organizers holds no responsibilities or liabilities of the personal articles of attendees at the venue against any kind of theft, lost, damage, due to any reason whatsoever. Delegates are entirely responsible for the safety of their own belongings.

Insurance

No insurance, of any kind, is included along with the registration in any of the events of the organization.

Transportation

Please note that transportation and parking is the responsibility of the registrant, Allied Academies will not be liable for any actions howsoever related to transportation and parking.

Press/Media

Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization and this conference is not associated with any commercial meeting company.

Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference after payment of complete registration fee. Once registration is complete, please contactstemcell@alliedevents.org

Cancellation Policy

All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

If, due to any reason, Allied academies postpone an event on the scheduled date, the participant is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Postponement of event

If, due to any reason, Allied academies postpone an event and the participant is unable or unwilling to attend the conference on rescheduled dates, he/she is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Transfer of registration

All registrations, after payment of complete registration fee, are transferable to other persons from the same organization, if in case the person is unable to attend the event. Request for transfer of registration must be made by the registered person in writing to contacts@alliedacademies.com Details must include the full name of replaced new registrant, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified. Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

This cancellation policy was last updated on April 04, 2015.

Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues are not covered under the cancellation policy of Allied academies, including the inability to obtain a visa.

Refund Policy.

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund policies apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overhead charges, following Refund Policy

Orders are available:

Accommodation Cancellation Policy

Accommodation Service Providers (Hotels) have their own cancellation policies which are applicable when cancellations are made less than 30 days prior to arrival. If in case the registrant wishes to cancel or amend the accommodation, he/ she is expected to inform the organizing authorities on a prior basis. Allied academies will advise the registrant to ensure complete awareness about the cancellation policy of your accommodation provider, prior to cancellation or modification of their booking.

See original here:
Stem Cell | Regenerative medicine | 2019 | Conference ...

Read More...

Domestic policy of the George W. Bush administration …

January 28th, 2019 5:45 pm

This article discusses the domestic policy of the George W. Bush administration.

Following the September 11 attacks, the Bush Administration proposed and Congress approved, a series of laws stated to be necessary in prosecuting the "War on Terror." These included a wide variety of surveillance programs, some of which came under heavy fire from civil liberties interest groups that criticized the new regulations for infringing upon certain civil liberties. The administration has also been criticized for refusing to back various security measures relating to port security in 2003 and 2004 and vetoing all US$39 million for the 2002 Container Security Initiative.

In early 2001, President Bush worked with Republicans in Congress to pass legislation changing the way the federal government regulated, taxed and funded charities and non-profit initiatives run by religious organizations. Although prior to the legislation it was possible for these organizations to receive federal assistance, the new legislation removed reporting requirements, which required the organizations to separate their charitable functions from their religious functions. Bush also created the White House Office of Faith Based and Community Initiatives.[1] Days into his first term, Bush announced his commitment to channeling more federal aid to faith-based service organizations. Bush created the Office of Faith-Based and Community Initiatives to assist faith-based service organizations. Critics claimed that this was an infringement of the separation of church and state.[2][3]

As Governor of Texas, Bush had opposed efforts to repeal the criminal prohibition on "homosexual conduct", the same law that the United States Supreme Court overturned in 2003, Lawrence v. Texas. During the 2000 campaign he did not endorse a single piece of gay rights legislation, although he did meet with an approved group of Log Cabin Republicans, a first for a Republican presidential candidate.[4]

In his first four years of office, his views on gay rights were often difficult to ascertain, but many experts feel that the Bush White House wanted to avoid bad publicity without alienating evangelical conservative Christian voters. Thus, he did not repeal President Clinton's Executive Order banning discrimination based on sexual orientation in the federal civilian government, but its critics felt it was ignored.[5] He did not attempt to repeal Don't ask, don't tell, nor try to change it. He threatened to veto the Matthew Shepard Act, which would have included sexual orientation in hate crimes.

While President Bush had always been on record as opposing the legal recognition of same-sex marriages, the 2004 Republican campaign strategy was to focus on "value issues" such as a Federal Marriage Amendment, that would prohibit same-sex couples from obtaining any legal recognition. President Bush endorsed this proposed amendment, but late in the campaign told ABC News and Larry King that he did not have a problem with state legislators enacting some type of civil unions legislation, although critics charged that the constitutional amendment he endorsed did not permit recognition of such unions.

Bush still expressed support for the Federal Marriage Amendment in his February 2, 2005 State of the Union addressand during the 2006 midterm election, but given that it did not even receive majority support in the Senate, has ignored this issue in his most recent public statements and speeches.

Bush was the first Republican president to appoint an openly gay man to serve in his administration, Scott Evertz, as director of the Office of National AIDS Policy.[6] In addition, during Bush's first term, his nominee as ambassador to Romania, Michael E. Guest, became the first openly gay man to be confirmed by the Senate as a U.S. ambassador. The first openly gay ambassador, James Hormel, received a recess appointment from Bill Clinton after the Senate failed to confirm the nomination.

According to a CNN exit poll, Bush's support from African-Americans increased during his presidency from 9% of the black vote in 2000 to 11% in 2004.[7] An increase in Ohio (from 9% to 16%,[7] each about 5%) may have helped give the victory to Bush over Kerry.

Although Bush expressed appreciation for the Supreme Court's ruling upholding the selection of college applicants for purposes of diversity, his Administration filed briefs against it. Bush has said he opposes government sanctioned and enforced quotas and racial preferences, but that the private and public sector should be encouraged to reach out to accomplished minorities to increase employment diversity.

In August 2005, a report by the United States Commission on Civil Rights states that "the government fails to seriously consider race-neutral alternatives as the Constitution requires."[8] Chairman Gerald A. Reynolds explained, "Federal agencies do not independently evaluate, conduct research, collect data, or periodically review programs to determine whether race-neutral strategies will provide an adequate alternative to race-conscious programs." Civil rights groups expressed concern that the report was an attack on affirmative action inconsistent with Grutter v. Bollinger.

In his first term, Bush appointed Colin Powell as Secretary of State. Powell was the first African-American man to serve in that position, and was succeeded by Condoleezza Rice: Rice became the first African-American woman to hold the post. In 2005, he appointed Alberto Gonzales as the United States Attorney General, the first Hispanic to hold that position.

Bush met with the National Urban League, the nation's oldest civil rights organization during his term of office as well.

President George W. Bush signed into law the Genetic Information Nondiscrimination Act (GINA).[9][10] The bill protects Americans against discrimination based on their genetic information when it comes to health insurance and employment. The issue had been debated for 13 years before becoming law. It is designed to protect citizens while not hindering genetic research.

On December 19, 2002, Bush signed into law H. R. 4664, far-reaching legislation to put the National Science Foundation (NSF) on a track to double its budget over five years and to create new mathematics and science education initiatives at both the pre-college and undergraduate level.[11] In the first three years of those five, the R&D budget has increased by fourteen percent.[12][13] Bush has long been dogged by criticism that his administration ignores or suppresses scientific advice.[14] Bush showed support for oceanography and space exploration; and supported sciences on reducing pollution. Bush generally was opposed to biology especially the science of human reproduction and reproductive health; and science with global warming. Bush supported "Teach the Controversy". Bush's positions were not always shared by his party.

President Bush supported adult stem cell research and umbilical cord blood stem cell research. However, Bush opposed any new embryonic stem cell research, and had limited the federal funding of existing research. Federal funding for embryonic stem cell research was first approved under President Clinton on January 19, 1999,[citation needed] but no money was to be spent until the guidelines were published. The guidelines were released under Clinton on August 23, 2000.[citation needed] They allowed use of unused frozen embryos. On August 9, 2001, before any funding was granted under these guidelines, Bush announced modifications to the guidelines to allow use of only existing stem cell lines.[15] While Bush claimed that more than 60 embryonic stem cell lines already existed from privately funded research, scientists in 2003 said there were only 11 usable lines, and in 2005 that all lines approved for Federal funding are contaminated and unusable.[16] Adult stem cell funding was not restricted and was supported by President Bush as a more viable means of research.

On January 14, 2004, Bush announced a Vision for Space Exploration,[17] calling for the completion of the International Space Station by 2010 and the retirement of the space shuttle while developing a new spacecraft called the Crew Exploration Vehicle under the title Project Constellation. The CEV would be used to return American astronauts to the Moon by 2018, with the objective of establishing a permanent lunar base, and eventually sending future manned missions to Mars.[18] To this end, the plan proposes that NASA's budget increase by five percent every year until it is capped at US$18 billion in 2008, with only inflationary increases thereafter.[19] The planned retirement of the Space Shuttle fleet in 2010 after the ISS is completed is also expected to free up US$5 billion to US$6 billion a year. The US$16.2 billion budget for 2005 proposed by NASA met with resistance from House and Senate spending committees, and the initiative was little-mentioned during the presidential campaign.[20] Nonetheless, the budget was approved with only minor changes shortly after the November elections.

Supporters believe that this plan will be an important part of what Bush set in place while in office. However, the policy has been criticized on two fronts. Firstly, critics have opined that the United States should deal with solving domestic issues before concentrating on space exploration. Secondly, of the funding over the next five years that Bush has proposed, only US$1 billion will be in new appropriations while the remaining US$11 billion will be reallocated from NASA's other programs, and therefore inadequate to fully realize this vision. Most of the spending for the new program, and most of the budget cuts for existing programs, are scheduled after the last year of the Bush presidency. It is unclear how the space vision will be reconciled with budgetary concerns in the longer term.

In January 2005, the White House released a new Space Transportation Policy fact sheet[21] which outlined the administration's space policy in broad terms and tied the development of space transport capabilities to national security requirements.

In December 2003, Bush signed legislation implementing key provisions of his Healthy Forests Initiative. Another subject of controversy is Bush's Clear Skies Initiative, which seeks to reduce air pollution through expansion of emissions trading.

Bush signed the Great Lakes Legacy Act of 2002 authorizing the federal government to begin cleaning up pollution and contaminated sediment in the Great Lakes, as well as the Brownfields Legislation in 2002, accelerating the cleanup of abandoned industrial sites, or brownfields, to better protect public health, create jobs, and revitalize communities.

Bush stated his reason for not supporting the Kyoto Protocol was that it unfairly targeted the United States while being deliberately lenient with certain developing countries, especially China and India. Bush stated, "The world's second-largest emitter of greenhouse gases is China. Yet, China was entirely exempted from the requirements of the Kyoto Protocol."

Bush also questioned the science behind the global warming phenomenon, insisting that more research be done to determine its validity.[22]

Upon arriving in office in 2001, President Bush withdrew United States support of the then-pending Kyoto Protocol, a UN Convention seeking to impose mandatory targets for reducing "greenhouse gas" emissions. Bush stated that human activity had not been proven to be the cause and cited concerns about the treaty's impact on the U.S. economy and pointed out that China and India had not signed on.[23] The Protocol entered into force on 16 February 2005. As of September 2011, 191 states have signed and ratified the protocol.[24] The only remaining signatory not to have ratified the protocol is the United States.

In 2002, the Bush Administration's EPA issued a Climate Action Report concluding that the climate changes observed over several decades "are likely mostly due to human activities, but we cannot rule out that some significant part of these changes is also a reflection of natural variability".[25] While the EPA report was initially hailed by some environmentalists critical of the Bush administration as a "180-degree turn on the science" reversing "everything the president has said about global warming since he took office," within days President Bush dismissed the report as being "put out by the bureaucracy," and reaffirmed his opposition to the Kyoto Protocol.[25]

The Bush Administration's stance on global warming, and in particular its questioning the consensus of scientists, would remain controversial in the scientific and environmental communities during his presidency. In 2004, the Director of NASA's Goddard Institute, James E. Hansen, came out publicly and harshly accusing the Administration of misinforming the public by suppressing the scientific evidence of the dangers of greenhouse gases, saying the Bush Administration wanted to hear only scientific results that "fit predetermined, inflexible positions" and edited reports to make the dangers sound less threatening in what he asserted was "direct opposition to the most fundamental precepts of science."[26][27] Other experts, such as former U.S. Department of Energy official Joseph Romm, have decried the Bush administration as a "denier and delayer" of government action essential to reduce carbon emissions and deter global warming.[28]

In 2005, Council on Environmental Quality chairman and former oil industry lobbyist Philip Cooney, was accused of doctoring and watering down descriptions of climate research from other government agencies. The White House denied these reports.[29] Two days later, Cooney announced his resignation[30] and conceded his role in altering the reports. "My sole loyalty was to the President and advancing the policies of his administration," he told the United States House Committee on Oversight and Government Reform.[31][32]

In addition, the administration thanked Exxon executives for the company's "active involvement" in helping to determine climate change policy, including the US stance on Kyoto.[33]

President Bush believes that global warming is real[34] and has said that he has consistently noted that global warming is a serious problem but asserted there is a "debate over whether it's manmade or naturally caused" and maintained that regardless of that debate his administration was working on plans to make America less dependent on foreign oil "for economic and national security reasons."[35]

The United States has signed the Asia Pacific Partnership on Clean Development and Climate, a pact that allows signatory countries to set goals for reducing greenhouse gas emissions individually, but with no enforcement mechanism. Republican Governor Arnold Schwarzenegger, along with 187 mayors from US towns and cities, have pledged to adopt Kyoto style legal limits on greenhouse gas emissions.[36]

For economic and national security reasons, Bush supported Alaska Senator Ted Stevens' plan to tap the oil reserves in a 2,000-acre (8km2) area of Alaska's 19 million acre (77,000km) Arctic National Wildlife Refuge. Pro-exploration supporters argue that U.S. companies have the most stringent environmental requirements, and that by doing the drilling in the middle of the winter, it would create a very small environmental footprint.[37]

Opponents stated that drilling would damage the coastal plain's fragile ecosystem and its wildlife. Proponents stated that modern techniques can extract the oil without damaging the environment [38]

Initially announced by President Bush in 2002,[39] the Clear Skies Initiative was aimed at amending the Clean Air Act to further reduce air pollution and expanded the emissions trading programs to include new pollutants such as mercury. The goal of the initiative was to reduce the sulfur dioxide, nitrogen oxide, and mercury emissions of power plants over the course of 15 years, while saving consumers millions of dollars.[39]

Among other things, the Clear Skies Act states that it would:[40][41][42]

The Natural Resources Defense Council, and its more than 500,000 members, examined the administration proposal and concluded it would harm public health, weaken current pollution fighting programs and worsen global warming. S. 385, the administration's bill to amend the Clean Air Act would:1. Allow power plant pollution to continue to inflict huge, avoidable health damages on the public. 2. Repeal or interfere with major health and air quality safeguards in current law. 3. Worsen global warming by ignoring CO2 emissions from the power sector.[43]

In January 2002, Bush signed the No Child Left Behind Act, with Democratic Senator Ted Kennedy as chief sponsor,[44] which aims to close the achievement gap, measures student performance, provides options to parents with children in low-performing schools, and targets more federal funding to low-income schools. Critics, including Senator John Kerry and the National Education Association, say schools were not given the resources to help meet new standards, although their argument is based on premise that authorization levels are spending promises instead of spending caps. The House Committee on Education and the Workforce said that the Department of Education's overall funding increased by US$14 billion since the enactment of NCLB in fiscal year 2001, going from US$42.6 billion to US$56.6 billion in fiscal year 2005.[citation needed] Some state governments are refusing to implement provisions of the act as long as they are not adequately funded.[45]

In January 2005, USA Today reported that the United States Department of Education had paid US$240,000 to African-American conservative political commentator Armstrong Williams "to promote the law on his nationally syndicated television show and to urge other black journalist to do the same."[46] Williams did not disclose the payments.

The House Education and Workforce Committee stated, "As a result of the No Child Left Behind Act, signed by Bush on January 8, 2002, the Federal government today is spending more money on elementary and High School (K-12) education than at any other time in the history of the United States.[citation needed] Funding increases have to a large degree been offset at the state level by increased costs associated with implementing NCLB, as well as the impacts of the economic downturn on education budgets.

According to the National Bureau of Economic Research, the economy suffered from a recession that lasted from March 2001 to November 2001. During the Bush Administration, Real GDP has grown at an average annual rate of 2.5%.[47]

Inflation under Bush has remained near historic lows at about 2-3% per year. The recession and a drop in some prices led to concern about deflation from mid-2001 to late 2003. More recently, high oil prices have caused concern about increasing inflation.

Long-term problems include inadequate investment in economic infrastructure, rapidly rising medical and pension costs of an aging population, sizable trade and budget deficits. Under the Bush administration, productivity has grown by an average of 3.76% per year, the highest such average in ten years.[48]

While the GDP recovered from a recession that some claim Bush inherited from the previous administration,[49] poverty has since worsened according to the Census Bureau. The percentage of the population below the poverty level increased in each of Bush's first four years, while it decreased for each of the prior seven years to an 11-year low. Although the poverty level increased the increase was still lower from 2000 to 2002 than it was from 1992 to 1997, which reached a peak of 39.3% in 1993. In 2002 the poverty rate was 34.6% which was almost equal to the rate in 1998, which was 34.5%. Poverty was at 12.7% in 2004.[citation needed]

President Bush won passage for two major tax cuts during his term in office: The Economic Growth and Tax Relief Reconciliation Act of 2001 and the Jobs and Growth Tax Relief Reconciliation Act of 2003. Collectively, they became known, analyzed, and debated as the "Bush tax cuts".

The cuts, scheduled to expire a decade after passage, increased the standard income tax deduction for married couples, eliminated the estate tax, and reduced marginal tax rates. Bush asked Congress to make the tax cuts permanent, but others wanted the cuts to be wholly or partially repealed even before their scheduled expiration, seeing the decrease in revenue while increasing spending as fiscally irresponsible.

Bush's supporters claim that the tax cuts increase the pace of economic recovery and job creation. They also claim that total benefits to wealthier individuals are a reflection of higher taxes paid. Individual income tax rate provisions in the 2001 law, for instance, created larger marginal tax rate decreases for people earning less than US$12,000 than any other earners.[50]

His opponents contest job prediction claims, primarily noting that the increase in job creation predicted by Bush's plan failed to materialize. They instead allege that the purpose of the tax cuts was intended to favor the wealthy and special interests, as the majority of benefit from the tax cut, in absolute terms, went to earners in the higher tax brackets. Bush's opponents additionally claim that the tax cuts are a major reason Bush reversed a national surplus into a historically large deficit.

In an open letter to Bush in 2004, more than 100 professors of business and economics at U.S. business schools ascribed this "fiscal reversal" to Bush's "policy of slashing taxes - primarily for those at the upper reaches of the income distribution."[51]

By 2004, these cuts had reduced federal tax revenues, as a percentage of the Gross Domestic Product, to the lowest level since 1959. With the NASDAQ crash and one quarter of negative growth in 2000 it was likely we were headed into a recession,[52] yet merely two years after the 2003 Bush tax cuts, federal revenues (in dollars) had reached a record high.[53] The effect of simultaneous record increases in spending and tax reductions was to create record budget deficits in absolute terms, though as recently as 1993, the deficit was slightly larger than the current 3.6% of the GDP. In the last year of the Clinton administration, the federal budget showed an annual surplus of more than US$230 billion.[54] Under Bush, the government returned to deficit spending. The annual deficit reached an absolute record of US$374 billion in 2003 and then a further record of $413 billion in 2004.[55][56]

President Bush expanded public spending by 70 percent, more than double the increase under President Clinton. Bush was the first president in 176 years to continue an entire term without vetoing any legislation.[57]

The tax cuts, recession, and increases in outlays all contributed to record budget deficits during the Bush administration. The annual deficit reached record current-dollar levels of US$374 billion in 2003 and US$413 billion in 2004. National debt, the cumulative total of yearly deficits, rose from US$5.7 trillion (58% of GDP) to US$8.3 trillion (67% of GDP) under Bush,[citation needed] as compared to the US$2.7 trillion total debt owed when Ronald Reagan left office, which was 52% of the GDP.[58]

According to the "baseline" forecast of federal revenue and spending by the Congressional Budget Office (in its January 2005 Baseline Budget Projections),[59] the budget deficits will decrease over the next several years. In this projection the deficit will fall to US$368 billion in 2005, US$261 billion in 2007, and US$207 billion in 2009, with a small surplus by 2012. The CBO noted, however, that this projection "omits a significant amount of spending that will occur this year and possibly for some time to come for U.S. military operations in Iraq and Afghanistan and for other activities related to the global War on Terrorism." The projection also assumes that the Bush tax cuts "will expire as scheduled on December 31, 2010." If, as Bush has urged, the tax cuts were to be extended, then "the budget outlook for 2015 would change from a surplus of US$141 billion to a deficit of US$282 billion." Other economists have disputed this, arguing that the CBO does not use dynamic scoring, to take into account what effect tax cuts would have on the economy.

Federal spending in constant dollars increased under Bush by 26% in his first four and a half years. Non-defense spending increased 18% in that time.[60] Of the US$2.4 trillion budgeted for 2005, about US$450 billion are planned to be spent on defense. This level is generally comparable to the defense spending during the cold war.[citation needed] Congress approved US$87 billion for Iraq and Afghanistan in November, and had approved an earlier US$79 billion package last spring. Most of those funds were for U.S. military operations in the two countries.

Former President Clinton's last budget featured an increase of 16% on domestic non security discretionary spending. Growth under President Bush was cut to 6.2% in his first budget, 5.5% in his second, 4.3% in his third, and 2.2% in his fourth.

Bush supports free trade policies and legislation but has resorted to protectionist policies on occasion. Tariffs on imported steel imposed by the White House in March 2002 were lifted after the World Trade Organization ruled them illegal. Bush explained that the safeguard measures had "achieved their purpose", and "as a result of changed economic circumstances", it was time to lift them.[61]

President Bush signed a large number of free trade agreements into law during his Presidency: Jordan (2001), Singapore and Chile (2004), Australia (2005), Dominican Republic, CAFTA, Morocco, Oman, and Bahrain (2006), and Oman and Peru (2009).

The Bush administration also launched trade negotiations with New Zealand, Thailand, Kuwait, Malaysia, Qatar, South Korea, Colombia, and Panama, with some being completed during President Obama's first term in office (2009-2013).

Some say economic regulation expanded rapidly during the Bush administration. President Bush is described by these observers as the biggest regulator since President Richard Nixon.[62] Bush administration increased the number of new pages in the Federal Registry, a proxy for economic regulation, from 64,438 new pages in 2001 to 78,090 in new pages in 2007, a record amount of regulation.[62] Economically significant regulations, defined as regulations which cost more than $100 million a year, increased by 70%.[62]

Spending on regulation increased by 62% from $26.4 billion to $42.7 billion.[62]

The contrary view on Bush's regulatory record is that he discouraged regulators from enforcing regulations and that counting pages in the Federal Register is a myopic method of measuring an administration's regulatory stance. The 2008 financial crisis occurred near the end of the Bush second term and represented an enormous failure for financial deregulation.[63]

Looking at the annual average unemployment rates for each of the eight years of Bush's presidency, the average of all eight figures, and thus of his entire presidency, is 5.26%, with a low of 4.6% for the years of 2006 and 2007, and a high of 6.0% for 2003.[64]

According to the Bureau of Labor Statistics, the number of unemployed was nearly 6.0 million in January 2001 and 6.9 million in September 2006. The unemployment rate was 4.2% in January 2001, 4.6% in September 2006, and 7.2% in December 2008. Employment peaked in late 1999 and declined through 2008.[65]

The Current Population Survey (aka Household Survey) measures the percentage of the population that is employed and unemployed. The result can be multiplied by population estimates to get total employment estimates. This survey has the advantage over the payroll survey in that it includes self-employed. The Household Survey is less accurate in producing total numbers since it requires population estimates and in that it samples many fewer people (60,000 households versus 400,000 business establishments). For better or worse, the Household Survey counts multiple jobs held by one person only once, and it includes government workers, farm workers, unpaid family workers, and workers absent without pay. The Household Survey indicates that the percentage of the population employed decreased from 64.4% in December 2000 and January 2001 to 62.1% in August and September 2003. By August 2005, it had recovered only to 62.9%. In absolute numbers, this corresponds to a drop of 1.6 million jobs but an eventual net gain of 4.7 million jobs during the Bush administration.[66]Private sector employment, as measured by private nonfarm payrolls, shrank over the 8 years of the George W. Bush presidency. There were modest gains in private-sector payroll employment during his first term, but these were more than offset by the shedding of workers by the private sector in his second term. There were 463,000 fewer private-sector payroll jobs when he left office than when he came into office.[67]

In 2004, a full chapter on Iraq's economy was excised from the Economic Report of the President, in part because it doesn't fit the "feel good" tone of the writing, according to White House officials.[citation needed]

In July 2002, Bush cut off U.S. funding to the United Nations Population Fund (UNFPA). Bush stated that the UNFPA supported forced abortions and sterilizations in the People's Republic of China.[68]

Bush signed the Medicare Act of 2003, which added prescription drug coverage to Medicare (United States), subsidized pharmaceutical corporations, and prohibited the Federal government from negotiating discounts with drug companies.

Bush signed the Partial-Birth Abortion Ban Act in 2003, having declared his aim to "promote a culture of life".

Bush is an advocate of the partial privatization of Social Security wherein an individual would be free to invest a portion of his Social Security taxes in personal retirement accounts.

Bush has called for major changes in Social Security, identifying the system's projected insolvency as a priority early in his second term. From January through April 2005, he toured the country, stopping in over 50 cities across the nation warning of an impending "crisis". Initially, President Bush emphasized his proposal for personalized accounts would allow individual workers to invest a portion of their Social Security Tax (FICA) into secured investments. The main advantage of personal accounts within Social Security is to allow workers to own the money they place into retirement that cannot be taken away by political whims.

Most Democrats and some Republicans are critical of such ideas, partly because of the large (US$1 trillion or more) federal borrowing the plan would require, which might actually worsen the imbalance between revenues and expenses that Bush pointed to as a looming problem; and partly because of the problems encountered by the United Kingdom's privatized pension plan. See Social Security debate (United States). In addition, many Democrats opposed changes that they felt were turning Social Security into a welfare program that would be politically vulnerable. Portions of Bush's bill exempting private companies from social security payments have led to complaints that Bush's plan was created to benefit private companies, and that it would turn Social Security into just another insurance program.

George W. Bush is a strong supporter of capital punishment. During his tenure as Governor of Texas, 152 people were executed in that state, maintaining its record as the leading state in executions.[69] As President of the United States, he has continued in his support for capital punishment, including presiding over the first federal execution in decades, that of convicted terrorist Timothy McVeigh. Although Bush's support of the death penalty is known, controversy broke in 1999 when journalist Tucker Carlson revealed that the Governor had mocked the plight of Karla Faye Tucker in an interview.

On his first day in office, President Bush implemented the Mexico City Policy; this policy required nongovernmental organizations receiving federal funds to agree not to perform abortions or to actively promote abortion as a method of family planning in other nations.[70][71] In 2002, President Bush signed the Born-Alive Infants Protection Act, which extends legal protection to infants born alive after failed attempts at induced abortion.[72] Also in 2002, President Bush withdrew funding from the United Nations Population Fund based on a finding that UNPF's activities facilitated China's one-child-only/forced abortion policy.[73] In 2003, President Bush signed the Partial Birth Abortion Ban Act into law;[74] that law was later upheld by the Supreme Court of the United States in Gonzales v. Carhart.[75] President Bush signed the Unborn Victims of Violence Act (Laci and Conner's Law), which provides that a person who commits certain federal violent crimes and thereby causes the death of, or bodily injury to, a fetus shall be guilty of a separate offense, whether or not the person knew the mother was pregnant or intended to harm the fetus.[76]

Bush staunchly opposes euthanasia. He supported Ashcroft's decision to file suit against the voter-approved Oregon Death with Dignity Act, which was ultimately decided by the Supreme Court in favor of the Oregon law.[77] As governor of Texas, however, Bush had signed a law which gave hospitals the authority to take terminally ill patients off of life support against the wishes of their spouse or parents, if the doctors deemed it medically appropriate.[78] This became an issue in 2005, when the President signed controversial legislation forwarded and voted on by only three members of the Senate to initiate federal intervention in the Terri Schiavo case.[79]

Bush signed the Amber Alert legislation into law on April 30, 2003, which was developed to quickly alert the general public about child abductions using various media sources.[80] On July 27, 2006 Bush signed the Adam Walsh Child Protection and Safety Act which establishes a national database requiring all convicted sex offenders to register their current residency and related details on a monthly instead of the previous yearly basis. Newly convicted sex offenders will also face longer mandatory incarceration periods.[81]

On June 15, 2006, Bush created the seventy-fifth, and largest, National Monument in U.S. history and the largest Marine Protected Area in the world with the formation of the Northwestern Hawaiian Islands National Monument.[82]

The Prison Rape Elimination Act of 2003 (PREA) is the first United States federal law passed dealing with the sexual assault of prisoners. The bill was signed into law on September 4, 2003. As a result, the National Prison Rape Elimination Commission was created to study the problem and recommend solutions. Federal funding for prisons also began to require detainment facilities to keep records on sexual assault. Failure to follow PREA requirements resulted in losing up to 5% of funding. New grants to prevent sexual assault were also created by the law. Significant support for the act came from Human Rights Watch, Concerned Women for America, Just Detention International, and numerous evangelical organizations.

In 2005-06, Bush emphasized the need for comprehensive energy reform and proposed increased funding for research and development of renewable sources of energy such as hydrogen power, nuclear power, ethanol, and clean coal technologies. Bush proposed the American Competitiveness Initiative which seeks to support increasing competitiveness of the U.S. economy, with greater development of advanced technologies, as well as greater education and support for American students. In the 2007 State of the Union speech, President Bush proposed a 20:10 policy, where, as a nation, the United States would be working to reduce 20% of the national energy usage in next 10 years by converting to ethanol.

Bush's imposition of a tariff on imported steel and on Canadian softwood lumber was controversial in light of his advocacy of free market policies in other areas. The steel tariff was later rescinded under pressure from the World Trade Organization. A negotiated settlement to the softwood lumber dispute was reached in April 2006, and the historic seven-year deal was finalized on July 1, 2006.[citation needed]

Go here to see the original:
Domestic policy of the George W. Bush administration ...

Read More...

Samples of Formatted References for Authors of Journal …

January 28th, 2019 5:44 pm

The International Committee of Medical Journal Editors (ICMJE) offers guidance to authors in its publication Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals (ICMJE Recommendations), which was formerly the Uniform Requirements for Manuscripts. The recommended style for references is based on the National Information Standards Organization NISO Z39.29-2005 (R2010) Bibliographic References as adapted by the National Library of Medicine for its databases.

Details, including fuller citations and explanations, are in Citing Medicine. (Note Appendix F which covers how citations in MEDLINE/PubMed differ from the advice in Citing Medicine.) For datasets (Item 43 below) and software on the Internet (Item 44 below), simplified formats are also shown.

See also #36. Journal article on the Internet and #43. Dataset description article.

1. Standard journal article

Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002 Jul 25;347(4):284-7.

List the first six authors, followed by et al. If there are more than six authors, list the first six authors, followed by et al. (Note: NLM now lists all authors.):

Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. Brain Res. 2002;935(1-2):40-6.

Optional: If a journal carries continuous pagination throughout a volume (as many medical journals do), omit the month and issue number.

Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. N Engl J Med. 2002;347:284-7.

Optional: Addition of a database's unique identifiers, such as the PubMed PMID, for the citation:

Forooghian F, Yeh S, Faia LJ, Nussenblatt RB. Uveitic foveal atrophy: clinical features and associations. Arch Ophthalmol. 2009 Feb;127(2):179-86. PubMed PMID: 19204236; PubMed Central PMCID: PMC2653214.

Optional: Addition of a clinical trial registration number:

Trachtenberg F, Maserejian NN, Soncini JA, Hayes C, Tavares M. Does fluoride in compomers prevent future caries in children? J Dent Res. 2009 Mar;88(3):276-9. PubMed PMID: 19329464. ClinicalTrials.gov registration number: NCT00065988.

2. Organization as author

Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002;40(5):679-86.

3. Both personal authors and organization as author (List all as they appear in the byline.)

Vallancien G, Emberton M, Harving N, van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1,274 European men suffering from lower urinary tract symptoms. J Urol. 2003;169(6):2257-61.

4. No author given

21st century heart solution may have a sting in the tail. BMJ. 2002;325(7357):184.

5. Article not in English

Ellingsen AE, Wilhelmsen I. Sykdomsangst blant medisin- og jusstudenter. Tidsskr Nor Laegeforen. 2002;122(8):785-7. Norwegian.

Optional: Translation of article title (MEDLINE/PubMed practice):

Ellingsen AE, Wilhelmsen I. [Disease anxiety among medical students and law students]. Tidsskr Nor Laegeforen. 2002 Mar 20;122(8):785-7. Norwegian.

6. Volume with supplement

Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache. 2002;42 Suppl 2:S93-9.

7. Issue with supplement

Glauser TA. Integrating clinical trial data into clinical practice. Neurology. 2002;58(12 Suppl 7):S6-12.

8. Volume with part

Abend SM, Kulish N. The psychoanalytic method from an epistemological viewpoint. Int J Psychoanal. 2002;83(Pt 2):491-5.

9. Issue with part

Ahrar K, Madoff DC, Gupta S, Wallace MJ, Price RE, Wright KC. Development of a large animal model for lung tumors. J Vasc Interv Radiol. 2002;13(9 Pt 1):923-8.

10. Issue with no volume

Banit DM, Kaufer H, Hartford JM. Intraoperative frozen section analysis in revision total joint arthroplasty. Clin Orthop. 2002;(401):230-8.

11. No volume or issue

Outreach: bringing HIV-positive individuals into care. HRSA Careaction. 2002 Jun:1-6.

12. Pagination in roman numerals

Chadwick R, Schuklenk U. The politics of ethical consensus finding. Bioethics. 2002;16(2):iii-v.

13. Type of article indicated as needed

Tor M, Turker H. International approaches to the prescription of long-term oxygen therapy [letter]. Eur Respir J. 2002;20(1):242.

Lofwall MR, Strain EC, Brooner RK, Kindbom KA, Bigelow GE. Characteristics of older methadone maintenance (MM) patients [abstract]. Drug Alcohol Depend. 2002;66 Suppl 1:S105.

14. Article containing retraction

Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry. 2002;63(2):169. Retraction of: Feifel D, Moutier CY, Perry W. J Clin Psychiatry. 2000;61(12):909-11.

Article containing a partial retraction:

Starkman JS, Wolder CE, Gomelsky A, Scarpero HM, Dmochowski RR. Voiding dysfunction after removal of eroded slings. J Urol. 2006 Dec;176(6 Pt 1):2749. Partial retraction of: Starkman JS, Wolter C, Gomelsky A, Scarpero HM, Dmochowski RR. J Urol. 2006 Sep;176(3):1040-4.

15. Article retracted

Feifel D, Moutier CY, Perry W. Safety and tolerability of a rapidly escalating dose-loading regimen for risperidone. J Clin Psychiatry. 2000;61(12):909-11. Retraction in: Feifel D, Moutier CY, Perry W. J Clin Psychiatry. 2002;63(2):169.

Article partially retracted:

Starkman JS, Wolter C, Gomelsky A, Scarpero HM, Dmochowski RR. Voiding dysfunction following removal of eroded synthetic mid urethral slings. J Urol. 2006 Sep;176(3):1040-4. Partial retraction in: Starkman JS, Wolder CE, Gomelsky A, Scarpero HM, Dmochowski RR. J Urol. 2006 Dec;176(6 Pt 1):2749.

16. Article republished with corrections

Mansharamani M, Chilton BS. The reproductive importance of P-type ATPases. Mol Cell Endocrinol. 2002;188(1-2):22-5. Corrected and republished from: Mol Cell Endocrinol. 2001;183(1-2):123-6.

17. Article with published erratum

Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther. 2000;22(10):1151-68; discussion 1149-50. Erratum in: Clin Ther. 2001;23(2):309.

18. Article published electronically ahead of the print version

Yu WM, Hawley TS, Hawley RG, Qu CK. Immortalization of yolk sac-derived precursor cells. Blood. 2002 Nov 15;100(10):3828-31. Epub 2002 Jul 5.

Back to top of page

19. Personal author(s)

Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.

20. Editor(s), compiler(s) as author

Gilstrap LC 3rd, Cunningham FG, VanDorsten JP, editors. Operative obstetrics. 2nd ed. New York: McGraw-Hill; 2002.

21. Author(s) and editor(s)

Breedlove GK, Schorfheide AM. Adolescent pregnancy. 2nd ed. Wieczorek RR, editor. White Plains (NY): March of Dimes Education Services; 2001.

22. Organization(s) as author

American Occupational Therapy Association, Ad Hoc Committee on Occupational Therapy Manpower. Occupational therapy manpower: a plan for progress. Rockville (MD): The Association; 1985 Apr. 84 p.

National Lawyer's Guild AIDs Network (US); National Gay Rights Advocates (US). AIDS practice manual: a legal and educational guide. 2nd ed. San Francisco: The Network; 1988.

23. Chapter in a book

Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002. p. 93-113.

24. Conference proceedings

Harnden P, Joffe JK, Jones WG, editors. Germ cell tumours V. Proceedings of the 5th Germ Cell Tumour Conference; 2001 Sep 13-15; Leeds, UK. New York: Springer; 2002.

25. Conference paper

Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer; 2002. p. 182-91.

26. Scientific or technical report

Issued by funding/sponsoring agency:

Yen GG (Oklahoma State University, School of Electrical and Computer Engineering, Stillwater, OK). Health monitoring on vibration signatures. Final report. Arlington (VA): Air Force Office of Scientific Research (US), Air Force Research Laboratory; 2002 Feb. Report No.: AFRLSRBLTR020123. Contract No.: F496209810049.

Issued by performing agency:

Russell ML, Goth-Goldstein R, Apte MG, Fisk WJ. Method for measuring the size distribution of airborne Rhinovirus. Berkeley (CA): Lawrence Berkeley National Laboratory, Environmental Energy Technologies Division; 2002 Jan. Report No.: LBNL49574. Contract No.: DEAC0376SF00098. Sponsored by the Department of Energy.

27. Dissertation

Borkowski MM. Infant sleep and feeding: a telephone survey of Hispanic Americans [dissertation]. Mount Pleasant (MI): Central Michigan University; 2002.

28. Patent

Pagedas AC, inventor; Ancel Surgical R&D Inc., assignee. Flexible endoscopic grasping and cutting device and positioning tool assembly. United States patent US 20020103498. 2002 Aug 1.

Back to top of page

29. Newspaper article

Tynan T. Medical improvements lower homicide rate: study sees drop in assault rate. The Washington Post. 2002 Aug 12;Sect. A:2 (col. 4).

30. Audiovisual material

Chason KW, Sallustio S. Hospital preparedness for bioterrorism [videocassette]. Secaucus (NJ): Network for Continuing Medical Education; 2002.

31. Legal Material

Public law:Veterans Hearing Loss Compensation Act of 2002, Pub. L. No. 107-9, 115 Stat. 11 (May 24, 2001).

Unenacted bill:Healthy Children Learn Act, S. 1012, 107th Cong., 1st Sess. (2001).

Code of Federal Regulations:Cardiopulmonary Bypass Intracardiac Suction Control, 21 C.F.R. Sect. 870.4430 (2002).

Hearing:Arsenic in Drinking Water: An Update on the Science, Benefits and Cost: Hearing Before the Subcomm. on Environment, Technology and Standards of the House Comm. on Science, 107th Cong., 1st Sess. (Oct. 4, 2001).

32. Map

Pratt B, Flick P, Vynne C, cartographers. Biodiversity hotspots [map]. Washington: Conservation International; 2000.

33. Dictionary and similar references

Dorland's illustrated medical dictionary. 29th ed. Philadelphia: W.B. Saunders; 2000. Filamin; p. 675.

Back to top of page

34. Forthcoming and Preprints

Go here to read the rest:
Samples of Formatted References for Authors of Journal ...

Read More...

Personalized Medicine | Moffitt

January 28th, 2019 5:44 pm

" );objDoc.close();// Print the document.objFrame.focus();objFrame.print();// Have the frame remove itself in about a minute so that// we don't build up too many of these frames.setTimeout(function(){jFrame.remove();},(60 * 1000));}/* === Sharing Tools === */ //Get current URL & Page Title//var urlShare = window.location.href;var urlShare = window.location.href; var titleShare = document.title;//Set width and height of pop-upvar widthShare = 560;var heightShare = 540;// Driver functions to create the various social share pop-upsfunction fbShare(url, title, descr, image, winWidth, winHeight) {var winTop = (screen.height / 2) - (winHeight / 2);var winLeft = (screen.width / 2) - (winWidth / 2);window.open('http://www.facebook.com/sharer.php?s=100&p[title]=' + title + '&p[summary]=' + descr + '&p[url]=' + url + '&p[images][0]=' + image, 'sharer', 'top=' + winTop + ',left=' + winLeft + ',toolbar=0,status=0,width=' + winWidth + ',height=' + winHeight);}function twShare(url, title, winWidth, winHeight) {var winTop = (screen.height / 2) - (winHeight / 2);var winLeft = (screen.width / 2) - (winWidth / 2);window.open('https://twitter.com/intent/tweet?url=' + url + '&text=' + encodeURI(title), 'sharer', 'top=' + winTop + ',left=' + winLeft + ',toolbar=0,status=0,width=' + winWidth + ',height=' + winHeight);}function goShare(url, winWidth, winHeight) {var winTop = (screen.height / 2) - (winHeight / 2);var winLeft = (screen.width / 2) - (winWidth / 2);window.open('https://plus.google.com/share?url=' + url, 'sharer', 'top=' + winTop + ',left=' + winLeft + ',toolbar=0,status=0,width=' + winWidth + ',height=' + winHeight);}//Click events to initiate social share pop-upvar myPageTitle = $('h1').text().trim();if (myPageTitle === "") {var myPageTitle = $('.profile-name').text().trim();}var myFormattedTitle = myPageTitle.replace("&", "and");var emailURL = window.location.href;$('#share-btn-email').attr('href', 'mailto:?subject=' + myFormattedTitle + '&body=Article from Moffitt Cancer Center.%0A' + emailURL );$("#share-btn-fb").click(function(){fbShare(urlShare,'Fb Share','Facebook share popup','http://goo.gl/dS52U',widthShare,heightShare)});$("#share-btn-tw").click(function(){twShare(urlShare,titleShare,widthShare,heightShare)});$("#share-btn-go").click(function(){goShare(urlShare,widthShare,heightShare)});//Open/close the share menuvar isSharing = false;$("#share-outer").click(function(){if(isSharing === false) {$("#share-wrapper").css("display","block");$(".share-btn-top").css('background-color','#fcfcfc');isSharing = true;} else {$("#share-wrapper").css("display","none");isSharing = false;$(".share-btn-top").css('background-color','#e1e1e1');}});/* === Print Page === */$(".print-btn").click(function(){$(".printable img").addClass('do-not-print');$(".printable").print();return( false );});});

Even though cancers may be found in the same part of the body and look similar under the microscope, we now understand that they can be quite different. That difference often appears in how that tumor type responds to therapy. Increasingly, that variation in response to treatment can reflect the changes that are found in the DNA of the tumor. Thats why Moffitt Cancer Center looks at every patients cancer as unique. We start with a precise diagnosis that tries to identify the specific DNA alternations in the tumor and then create an individualized treatment plan that has the best chance of beating your cancer. Our team approach ensures a full range of specialists are collaborating to look at your cancer from every perspective.

The ultimate goal of personalized medicine at Moffitt is to create and share new, targeted treatments that will improve outcomes, cure disease, extend survivorship and improve quality of life for patients regardless of where they live. This is accomplished through existing clinical programs as well as ongoing research into how best to develop the right diagnosis and treatment plan for each individual.

Our efforts include:

DeBartolo Family Personalized Medicine InstituteThe DeBartolo Family Personalized Medicine Institute provides the hub for personalized care and research at Moffitt. Created by a generous donation from the DeBartolo Family Foundation, the DFPMI was created in 2012 to revolutionize the discovery, delivery and effectiveness of cancer care on an international scale.

Department of Individualized Cancer ManagementThe Department of Individualized Cancer Management includes five high impact and clinically oriented departments under the leadership of Dr. Howard McLeod: Adolescent & Young Adult, Gene Home, Genetic Risk Assessment Service, Personalized Cancer Medicine and the Senior Adult Oncology Program. The Personalized Cancer Medicine department is comprised of the Personalized Medicine Clinical Service (PMCS) and Clinical Genomics Action Committee (CGAC). PMCS and CGAC were developed as pathways for direct clinical translation of results from genomic testing. PMCS provides consultation and interpretation of the tumor genetic sequencing results for Moffitt patients and serves as a resource to Moffitt Physicians for input and advice regarding personalized medicine. CGAC serves as Moffitts unique molecular tumor board and includes a diverse team with expertise from various disciplines. Dr. McLeod, a renowned expert on the role of genetics on the individuals response to cancer therapies, is the Medical Director for the DeBartolo Family Personalized Medicine Institute.

Total Cancer CareMoffitt Cancer Center's Total Cancer Care initiative is an ambitious research partnership between patients, doctors and researchers to improve all aspects of cancer prevention and care. Patients participate by donating information and tissue. Researchers use the information to learn about all issues related to cancer and how care can be improved. Physicians use the information to better educate and care for patients.

Clinical PathwaysMoffitts clinical pathways are a model for providing evidence-based, consensus-driven, cost-effective cancer care. Each of the 51 disease-specific pathways that Moffitt has developed offers a detailed road map for physicians to provide state-of-the-art cancer care. The pathways demonstrate how to integrate evidence-based medicine with available technology to standardize, benchmark, measure and improve cancer care.

Molecular Diagnostics LaboratoryThe Morsani Molecular Diagnostics Laboratory is revolutionizing cancer diagnostics by using the most advanced genetic testing tools available to improve the precision in the patient care we provide. Studies show as many as 30 percent of initial cancer diagnoses are revised to indicate a different type of cancer. This lab seeks to reduce that number by developing clinical biomarkers that can help identify the right drug for a particular patient or determine if a specific clinical trial is a good match for a patient with a certain tumor gene mutation.

ORIENThe Oncology Research Information Exchange Network (ORIEN) is a unique research partnership among North Americas top cancer centers that recognizes collaboration and access to data as the key to cancer discovery. Through ORIEN, founders Moffitt and The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus leverage multiple data sources and match patients to targeted treatments. Partners have access to one of the worlds largest clinically annotated cancer tissue repositories and data from more than 100,000 patients who have consented to the donation for research.

View post:
Personalized Medicine | Moffitt

Read More...

What are Adult Stem Cells? | Adult Stem Cell Treatment

January 28th, 2019 5:44 pm

The primary role of adult stem cells in humans is to maintain and repair the tissue in which they are found. While we call them adult stem cells, they are more accurately called somatic (from the Greek word soma = body) because they come virtually any body tissue, not only in adults but children and babies as well.

Stem cells are very flexible cells, sometimes considered immature, that have not developed to a final specialized cell type (like skin, liver, heart, etc.) Since they have not yet specialized, stem cells can respond to different signals and needs in the body by becoming any of the various cell types needed, e.g., after an injury to repair an organ. In that sense they are a bit like a maintenance crew that keeps repairing and replacing damaged or worn out cells in the body.

A stem cell is essentially a blank cell, capable of becoming another more differentiated cell type in the body, such as a skin cell, a muscle cell, or a nerve cell. Microscopic in size, stem cells are big news in medical and science circles because they can be used to replace or even heal damaged tissues and cells in the body. They can serve as a built-in repair system for the human body, replenishing other cells as long as a person is still alive.

Adult stem cells are a natural solution. They naturally exist in our bodies, and they provide a natural repair mechanism for many tissues of our bodies. They belong in the microenvironment of an adult body, while embryonic stem cells belong in the microenvironment of the early embryo, not in an adult body, where they tend to cause tumors and immune system reactions.

Most importantly,adult stem cells have already been successfully used in human therapies for many years.As of this moment,no therapies in humans have ever been successfully carried out using embryonic stem cells.New therapies using adult type stem cells, on the other hand, are being developed all the time.

Stem Cells are being used today to help people suffering from dozens of diseases and conditions. This list reveals the wide range of applications that adult stem cells are having right now:

Cancers:

Auto-Immune Diseases

Cardiovascular

Ocular

Neural Degenerative Diseases and Injuries

Anemias and Other Blood Conditions

Wounds and Injuries

Other Metabolic Disorders

Liver Disease

The primary reason would be the ethics, since getting embryonic stem cells requires destruction of a young human embryo. The other, practical reasons are that people feel money spent on embryonic stem cell research could be better spent on other stem cell research.

The biggest misconception people have about stem cell research is that it is only embryonic that are useful. In fact, other stem cell types are proving to be much more useful. The best stem cells for patients are Adult Stem Cells; these are taken from the body (e.g., bone marrow, muscle, even fat tissue) or umbilical cord blood and can be used to treat dozens of diseases and conditions. Over 1 million people have already been treated with adult stem cells. (versus no proven success with embryonic stem cells.)https://lozierinstitute.org/fact-sheet-adult-stem-cell-research-transplants/Yet most people dont know about adult stem cells and their practical success.

Another type of stem cell that is proving very useful is induced pluripotent stem cells (iPS cells.) These can be made from any cell, such as skin, and from any person. They act like embryonic stem cells, but are made from ordinary cells and so dont require embryo destruction, making them an ethical source for that type of cell. They have already been used to create lab models of different diseases.

Visit link:
What are Adult Stem Cells? | Adult Stem Cell Treatment

Read More...

Is longevity determined by genetics? – Genetics Home …

January 28th, 2019 5:43 pm

The duration of human life (longevity) is influenced by genetics, the environment, and lifestyle. Environmental improvements beginning in the 1900s extended the average life span dramatically with significant improvements in the availability of food and clean water, better housing and living conditions, reduced exposure to infectious diseases, and access to medical care. Most significant were public health advances that reduced premature death by decreasing the risk of infant mortality, increasing the chances of surviving childhood, and avoiding infection and communicable disease. Now people in the United States live about 80 years on average, but some individuals survive for much longer.

Scientists are studying people in their nineties (called nonagenarians) and hundreds (called centenarians, including semi-supercentenarians of ages 105-109 years and supercentenarians, ages 110+) to determine what contributes to their long lives. They have found that long-lived individuals have little in common with one another in education, income, or profession. The similarities they do share, however, reflect their lifestylesmany are nonsmokers, are not obese, and cope well with stress. Also, most are women. Because of their healthy habits, these older adults are less likely to develop age-related chronic diseases, such as high blood pressure, heart disease, cancer, and diabetes, than their same-age peers.

The siblings and children (collectively called first-degree relatives) of long-lived individuals are more likely to remain healthy longer and to live to an older age than their peers. People with centenarian parents are less likely at age 70 to have the age-related diseases that are common among older adults. The brothers and sisters of centenarians typically have long lives, and if they develop age-related diseases (such as high blood pressure, heart disease, cancer, or type 2 diabetes), these diseases appear later than they do in the general population. Longer life spans tend to run in families, which suggests that shared genetics, lifestyle, or both play an important role in determining longevity.

The study of longevity genes is a developing science. It is estimated that about 25 percent of the variation in human life span is determined by genetics, but which genes, and how they contribute to longevity, are not well understood. A few of the common variations (called polymorphisms) associated with long life spans are found in the APOE, FOXO3, and CETP genes, but they are not found in all individuals with exceptional longevity. It is likely that variants in multiple genes, some of which are unidentified, act together to contribute to a long life.

Whole genome sequencing studies of supercentenarians have identified the same gene variants that increase disease risk in people who have average life spans. The supercentenarians, however, also have many other newly identified gene variants that possibly promote longevity. Scientists speculate that for the first seven or eight decades, lifestyle is a stronger determinant of health and life span than genetics. Eating well, not drinking too much alcohol, avoiding tobacco, and staying physically active enable some individuals to attain a healthy old age; genetics then appears to play a progressively important role in keeping individuals healthy as they age into their eighties and beyond. Many nonagenarians and centenarians are able to live independently and avoid age-related diseases until the very last years of their lives.

Some of the gene variants that contribute to a long life are involved with the basic maintenance and function of the bodys cells. These cellular functions include DNA repair, maintenance of the ends of chromosomes (regions called telomeres), and protection of cells from damage caused by unstable oxygen-containing molecules (free radicals). Other genes that are associated with blood fat (lipid) levels, inflammation, and the cardiovascular and immune systems contribute significantly to longevity because they reduce the risk of heart disease (the main cause of death in older people), stroke, and insulin resistance.

In addition to studying the very old in the United States, scientists are also studying a handful of communities in other parts of the world where people often live into their nineties and olderOkinawa (Japan), Ikaria (Greece), and Sardinia (Italy). These three regions are similar in that they are relatively isolated from the broader population in their countries, are lower income, have little industrialization, and tend to follow a traditional (non-Western) lifestyle. Unlike other populations of the very old, the centenarians on Sardinia include a significant proportion of men. Researchers are studying whether hormones, sex-specific genes, or other factors may contribute to longer lives among men as well as women on this island.

Martin GM, Bergman A, Barzilai N. Genetic determinants of human health span and life span: progress and new opportunities. PLoS Genet. 2007 Jul;3(7):e125. PubMed: 17677003. Free full-text available from PubMed Central: PMC1934400.

Sebastiani P, Gurinovich A, Bae H, Andersen S, Malovini A, Atzmon G, Villa F, Kraja AT, Ben-Avraham D, Barzilai N, Puca A, Perls TT. Four genome-wide association studies identify new extreme longevity variants. J Gerontol A Biol Sci Med Sci. 2017 Oct 12;72(11):1453-1464. doi: 10.1093/gerona/glx027. PubMed: 28329165.

Sebastiani P, Solovieff N, Dewan AT, Walsh KM, Puca A, Hartley SW, Melista E, Andersen S, Dworkis DA, Wilk JB, Myers RH, Steinberg MH, Montano M, Baldwin CT, Hoh J, Perls TT. Genetic signatures of exceptional longevity in humans. PLoS One. 2012;7(1):e29848. doi: 10.1371/journal.pone.0029848. Epub 2012 Jan 18. PubMed: 22279548. Free full-text available from PubMed Central: PMC3261167.

Wei M, Brandhorst S, Shelehchi M, Mirzaei H, Cheng CW, Budniak J, Groshen S, Mack WJ, Guen E, Di Biase S, Cohen P, Morgan TE, Dorff T, Hong K, Michalsen A, Laviano A, Longo VD. Fasting-mimicking diet and markers/risk factors for aging, diabetes, cancer, and cardiovascular disease. Sci Transl Med. 2017 Feb 15;9(377). pii: eaai8700. doi: 10.1126/scitranslmed.aai8700. PubMed: 28202779.

Young RD. Validated living worldwide supercentenarians, living and recently deceased: February 2018. Rejuvenation Res. 2018 Feb 1. doi: 10.1089/rej.2018.2057. [Epub ahead of print] PubMed: 29390945.

Follow this link:
Is longevity determined by genetics? - Genetics Home ...

Read More...

Contact Us – Stemcell Technologies

January 28th, 2019 5:43 pm

Select your desired country to view specific contact information for that location: Please choose a country... Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegowina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic East Timor Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France France, Metropolitan French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-Bissau Guyana Haiti Heard and Mc Donald Islands Honduras Hong Kong, China Hungary Iceland India Indonesia Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Republic of Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macau, China Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montserrat Morocco Mozambique Myanmar (Burma) Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Republic of Serbia Reunion Romania Russia Rwanda Saint Kitts and Nevis Saint Lucia Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Seychelles Sierra Leone Singapore Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia South Africa South Georgia and South S.S. Spain Sri Lanka St. Helena St. Pierre and Miquelon Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Tahiti Taiwan, China Tajikistan Tanzania, United Republic of Thailand The Democratic Republic of Congo Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu U.S. Minor Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City State Venezuela Vietnam Virgin Islands (British) Virgin Islands (U.S.) Wallis and Futuna Islands Western Sahara Yemen Yugoslavia (Serbia and Montenegro) Zambia Zimbabwe

See more here:
Contact Us - Stemcell Technologies

Read More...

Stem Cell Treatment UK – Stem Cell Therapy Clinic

January 28th, 2019 5:42 pm

Get In Touch

Over 60 disabling illnesses including , neurological , organ damage , metabolic disorders , blood disorders , arthiritis.... please read more for extensive list

See what people say about their personal improvements , and experiences whilst in our worldwide clinics

See my own story unfold , after recieving life changing treatment in dec 2015 watch how i improve over the coming weeks and months

Welcome to my site providing a direct link to Stem Cell Treatment clinics to improve the health of UK and worldwide residents

Groundbreaking modern technology has brought us a completely natural, drugfree way to heal the

human body. Our primary task is to use your own unique stem cells for the treatment of your own body. Using advanced medical knowledge we can now activate dormant cells (adipose mesenchymal stem cells) to differentiate into the cells we need, and then they can replace the damaged cells. Symtoms become less obvious and disappear, giving relief and the chance to regain a normal functioning body and life!

Having been to a private clinic and experiencing life changing improvements to my own health, I want to let more people know about stemcells and that there is HOPE, to end many disabling conditions that we are led to believe are inevitably going to get worse. By contacting me I will help you to find the right treatment for your individual needs, at a clinic in a country where you will be treated as a distinguished guest, at a price more affordable than you will expect. I can speak from experience, and will gladly guide and help you through the whole process. Please explore my site, read the testimonials and hit the contact me button to speak to some of them! That much is free, and to feel better is truly miraculous!

See original here:
Stem Cell Treatment UK - Stem Cell Therapy Clinic

Read More...

what is hsct, what is Hematopioetic Stem Cell Transplant …

January 28th, 2019 5:42 pm

what is hsct, what is Hematopioetic Stem Cell Transplant for ms, hsct stops all types of ms | HSCT STOPS MS Skip to contentWHAT IS HSCT? A COMPREHENSIVE DESCRIPTIONWith HSCT currently gaining a lot of attention in the main stream media for its huge success in giving people with MS new hope and the epic possibility of totally halting disease progression, more and more people are asking: what is HSCT? HSCT stops MS! HSCT or Hematopioetic Stem Cell Transplant, is the only existing scientifically proven treatment, currently available that completely halts disease progression of Multiple Sclerosis. It is not a new procedure as such, as it has been used to treat cancer since the 1960s, but it is a relatively new treatment for MS. Perhaps new is the wrong word The first HSCT performed specifically for an autoimmune disease (uveitis) was performed in 1985 by Prof. Shimon Slavin in Israel. The patient remains cured today. The first HSCT performed specifically for MS was at George Papanicolaou General Hospital, Thessaloniki, Greece in 1995. However, there were many observational case studies before then focusing on the success of HSCT for MS patients that were transplanted for cancer who simultaneously had their MS halted, as an unanticipated side effect of the treatment. All of the early studies that followed, also clearly established the now (well understood) probability that transplantation earlier in the disease life cycle is more beneficial than transplanting later in the disease evolution, when there is a greater degree of irreversible disability. Dr Burt at North Western University, Chicago, started HSCT treatment back in 1996. Prior to that, while he was a Fellow working at Johns Hopkins Hospital in Baltimore, he noticed that the leukemia patients he was treating needed to be re-vaccinated because the protection from childhood diseases like the measles and mumps was being lost. The cells affected by transfusion treatments were losing the memory of these original childhood vaccinations.Maybe, thought Dr. Burt, if we could get bad, diseased cells to lose their memory, we could reprogram them with good memories and help patients with autoimmune diseases. This reprogramming would depend on adult stem cellstiny building blocks found in the bodyif it was going to work.He first tried out his idea on animals in the research lab andit worked! Not long afterwards the FDA gave its approval for the adult stem cell therapy to be used on people suffering from Multiple Sclerosis, and again, it worked. Now, 14 years later, Burt and his team of researchers at Northwestern University are using this technique to help treat patients suffering from some 23 different diseases. There is no ethical dilemma as the treatment uses adult stem cells extracted from the patients own blood, and no embryonic stem cells are involved.Because the procedure involves the use of chemotherapy the treatment is not the most comfortable and is unfortunately quite expensive. That said many who have completed the procedure successfully attest to the fact that it is not unbearable by any means, and the chemotherapy part of the procedure is a short targeted dose that lasts for days as opposed to cancer treatments which can drag out over a much longer period. Indeed it is very different from the chemo used for cancer patients altogether. One should bear in mind that when cancer patients undergo chemotherapy they are more than likely very sick going in to the procedure and therefore would experience a greater degree of discomfort than someone relatively fit except for MS. Please refer to the blog links page to read first hand accounts of how individuals who have been treated already dealt with the procedure and how it has affected them. Please see: http://www.hsctstopsms.com/how-hsct-works/.What cannot be denied however is that to date HSCT is the only scientifically proven treatment that STOPS underlying disease progression in all types of MS and restores normal immune self-tolerance and produces lasting curative symptomatic improvement for the majority of MS patients. To date over 2,000 patients have been treated world wide, and the number continues to rise daily. It is important to mention here, that where you can go for treatment and whether you qualify, is determined by a variety of different criteria. We aim to help clarify your options and help you to decide the best place to apply for your own treatment.While this treatment is standard procedure for treating cancer patients (thousands of patients are treated annually), it is not standard treatment for people suffering from Multiple Sclerosis. There are a very small number of facilities Worldwide currently performing this procedure for MS. The type of MS that you have also plays a part in treatment; see http://www.hsctstopsms.com/types-of-ms/. The hope is that more will open in the early future as the demand increasingly continues to outweigh the supply, and that the cost of being treated will reduce accordingly, as the protocol efficiency is optimized. (Please refer to the menu item entitled Choosing a facility to learn more).Many who have already had HSCT say that one of the best parts of being treated is that halting the underlying disease progression of MS gives them back a future. George Goss, who had HSCT in 2009, an inspirational pioneer in promoting HSCT after he underwent the procedure in Heidelberg five years ago, describes this as pure gold. (Please see his blog: http://themscure.blogspot.co.uk/ and check out his HSCT forum on Facebook: HematopioeticStemCellTransplantMS&AutoimmuneDiseases, where he has provided invaluable information and support for those seeking HSCT). Living with MS is both frightening and uncertain. Little is known about what sparks rapid disease progression with no warning. One can go 10 years with little or no symptoms and then suddenly find oneself in a wheelchair in the space of a few months. It has been described as a Tiger that cannot be tamed. HSCT removes this Sword of Damocles hanging over ones heads and gives one the gift of hope and the luxury of planning a future with loved ones. Unless you live with MS you can have no concept of how magic this prospect can be! (Please see What it is like living with MS in the menu.)

Excerpt from:
what is hsct, what is Hematopioetic Stem Cell Transplant ...

Read More...

Veterinary medicine in the United States – Wikipedia

January 28th, 2019 5:41 pm

Veterinary medicine in the United States is the performance of veterinary medicine in the United States, normally performed by licensed professionals, and subject to provisions of statute law which vary by state. Veterinary medicine is normally led by veterinary physicians, normally termed veterinarians or vets.

Veterinarians are often assisted by paraveterinary workers including veterinary technicians and veterinary assistants, and in some cases, these para-professionals may perform work on their own.

Dependent on the jurisdiction, other professionals may be permitted to perform some animal treatment, through either specific exemptions in the law or through a lack of prohibitive legislation. This can include manipulation techniques such as physiotherapy, chiropractic and osteopathy, or animal-specific professions such as horse and cattle hoof trimmers, equine dental technicians, and technicians who specialize in cattle artificial insemination.

The Veterinarian's Oath was adopted by the American Veterinary Medical Association's House of Delegates July 1969, and amended by the AVMA Executive Board, November 1999 and December 2010.

Being admitted to the profession of veterinary medicine, I solemnly swear to use my scientific knowledge and skills for the benefit of society through the protection of animal health and welfare, the prevention and relief of animal suffering, the conservation of animal resources, the promotion of public health, and the advancement of medical knowledge.

I will practice my profession conscientiously, with dignity, and in keeping with the principles of veterinary medical ethics. I accept as a lifelong obligation the continual improvement of my professional knowledge and competence.

In order to practice, veterinarians must obtain a degree in veterinary medicine, followed by gaining a license to practice. Previously, veterinary degrees were available as a bachelor's degree, but now all courses result in the award of a doctorate and are therefore awarded a Doctor of Veterinary Medicine (DVM) if the degree is awarded in English, or a Veterinariae Medicinae Doctoris ("Doctor of Veterinary Medicine") (VMD) if the degree is awarded in Latin.

There is a high level of competition for admission to veterinary schools; there are currently only twenty eight veterinary schools in the United States which meet the accreditation standards set by the Council on Education of the American Veterinary Medical Association (AVMA), and five in Canada. Entrance requirements vary among veterinary schools, and various pre-professional degree programs have been developed to assist undergraduates in meeting these requirements. Such pre-vet programs are thus similar in concept to pre-med programs, and are often housed in Agricultural Biology,[1] Animal Science,[2] or Biological Science[3] programs.

Following qualification from the doctoral degree, the prospective veterinarian must receive a passing grade on the North America Veterinary Licensing Exam.[4] This exam is completed over the course of eight hours, and consists of 360 multiple-choice questions. This exam covers all aspects of veterinary medicine, as well as visual material designed to test diagnostic skills.

The median salary for starting veterinarians in 2016 was $74,690 in the United States according to U.S. Money News, while the lowest paid graduates earned approximately $53,000 annually. Montana had the lowest state average, while Michigan, Illinois and Hawaii had the highest.

The average income for a private practice associate in the United States was $158,000 in 2016. According to DVM360 most practice owner's paid themselves based on production, including a 3-4% management fee plus a 4.5% "return on investment" fee dependent on the value of their business. We know from industry standards that the average owner of a veterinary practice earns approximately $282,000 per year base salary. These increased values exceed those of public practice including uniformed services and government. In Australia, the profession wide average income was $67,000 in 2011 and this has declined compared to other professions for the past 30 years whilst graduate unemployment has doubled between 2006 and 2011.[5]

As opposed to human medicine, general practice veterinarians greatly outnumber veterinary specialists. Most veterinary specialists work at the veterinary schools, or at a referral center in large cities. As opposed to human medicine, where each organ system has its own medical and surgical specialties, veterinarians often combine both the surgical and medical aspect of an organ system into one field. The specialties in veterinary medicine often encompass several medical and surgical specialties that are found in human medicine.

Veterinary specialties are accredited in North America by the AVMA through the American Board of Veterinary Specialties.[6] While some veterinarians may have areas of interest outside of recognized specialties, they are not legally specialists.

According to a veterinary survey top paying specialties include veterinary anesthesiology ($389,105 median salary in 2008), veterinary ophthalmology ($215,120 median salary in 2009), veterinary nutrition ($202,368 average salary in 2008), and veterinary general surgery ($183,902 average salary in 2008).[7]

Veterinary technicians are the primary paraveterinary workers in the US and assist the veterinarian in the role of a nurse (and in most other anglophone countries, the equivalent role is called a veterinary nurse), providing trained support. The requirements for technicians vary by state, but in most cases, technicians are graduates of two or four year college-level programs and are legally qualified to assist veterinarians in many medical procedures.

Some states choose to license technicians, so that only people with appropriate qualifications are able to fulfill the role, but this is not the case in all jurisdictions.

Veterinary technology as an organized and credentialed career option is relatively young, only existing since the mid 20th century, although it began in 1908 when the Canine Nurses Institute was established in England, and as such is still struggling for recognition in many parts of the world. The first training program for technicians in the United States was established by the Air Force in 1951. The first civilian program was established ten years later in 1961 at the State University of New York (SUNY) Agricultural and Technical College at Delhi. In 1965 Walter Collins, a veterinarian, received federal funding to develop model curricula for training technicians. He produced several guides over the next seven years, and for this work he is considered the "father of veterinary technology" in the United States.[8]

Technical skills include: venipuncture; collecting urine; performing skin scrapings; taking and processing radiographs; and performing routine lab procedures and tests in: hematology, blood chemistry, microbiology, urinalysis, and microscopy. They assist the veterinarian with physical examinations that help determine the nature of the illness or injury. Veterinary technicians also induce and maintain anesthesia, and administer medications, fluids and blood products as prescribed by the veterinarian. Tasks in patient care include: recording temperature, pulse and respiration, dressing wounds, applying splints and other protective devices, and dental procedures. They perform catheterizations urinary, arterial, and venous; ear flushes; intravenous feedings and tube feedings. Equipment use includes operating various types of patient monitors and imaging devices to include electrocardiographic, radiographic and ultrasonographic equipment. Larger referral practices and teaching hospitals may also find veterinary technicians operating computed tomography equipment, magnetic resonance imagers, gamma cameras and other advanced medical devices. Veterinary technicians commonly assist veterinarians in surgery by providing correct equipment and instruments and by assuring that monitoring and support equipment are in good working condition. They may also maintain treatment records and inventory of all pharmaceuticals, equipment and supplies, and help with other administrative tasks within a veterinary practice such as client education. Unlike their more specialized counterparts among medical paraprofessionals, the veterinary technician is usually the only paraprofessional found in a veterinary practice and is thus often called upon to be a jack-of-all-trades.

To become a credentialed veterinary technician, one must complete a two-year or three-year AVMA credentialled degree, most of which result in the awarding of an associate of applied science degree in veterinary technology (those completing a four-year AVMA accredited school gain a bachelor's degree are considered veterinary technologists though the distinction is rarely made with the term technician being used generally.[9]

The education a credentialed technician receives is in-depth and crucial for medical understanding and to give proper health care. The American Veterinary Medical Association (AVMA) is responsible for accrediting schools with either Associate's degrees or Bachelor's degrees, though in some states or provinces this is not necessary. The AVMA also accredits schools that offer distance education. As a requirement of AVMA-accreditation, all distance learning programs require a significant amount of practical clinical experience before the student will be allowed to graduate.

Beyond credentialing as a veterinary technician specialty certification is also available to technicians with advanced skills. To date there are specialty recognitions in: emergency & critical care, anesthesiology, dentistry, small animal internal medicine, large animal internal medicine, cardiology, oncology, neurology, zoological medicine, equine veterinary nursing, surgery, behavior, nutrition, clinical practice (canine/feline, exotic companion animal, and production animal sub-specialties), and clinical pathology. Veterinary Technician Specialists carry the additional post-nominal letters "VTS" with their particular specialties indicated in parentheses. As veterinary technology evolves, more specialty academy recognitions are anticipated.

Non-credentialed personnel who perform similar tasks to veterinary technicians are usually referred to as veterinary assistants though the term technician is often applied generously. In many states, a veterinary assistant cannot legally perform as many procedures as a technician. Veterinary assistants often have no formal education related to veterinary medicine or veterinary technology, however, NAVTA recently approved the designation of Approved Veterinary Assistant (AVA) for those successfully completing approved educational programs. In larger facilities with tiered hierarchies veterinary assistants typically assist veterinary technicians in their duties.

Most states in the US allow for malpractice lawsuit in case of death or injury to an animal from professional negligence. Usually the penalty is not greater than the value of the animal. For that reason, malpractice insurance for veterinarians usually is well under $500 a year, compared to an average of over $15000 a year for a human doctor.[10] Some states allow for punitive penalty, loss of companionship, and suffering into the award, likely increasing the cost of veterinary malpractice insurance and the cost of veterinary care. Most veterinarian carry much higher cost business insurance, worker's compensation, and facility insurance to protect their clients and workers from injuries inflicted by animals.

Read the original:
Veterinary medicine in the United States - Wikipedia

Read More...

Stem Cell Treatment for Dementia | Stem Cell Doctors …

January 28th, 2019 5:41 pm

Mary Holler, age 82, of Marco Island Florida is smiling again. Mary was suffering from dementia.

She and her husband sought Stem Cell Dementia Treatment.

She felt uneasy with her ability to function on a daily basis. Now, after undergoing a successful stem cell dementia treatment earlier this month, Mary is her old self again. She doesnt ask her husband, Peter, the same question 3-4 times in an hour anymore. Peter Holler, age 83, had become very concerned that his wife of 60 years was slowly losing her memory. She had been on medications for memory loss for several years but the deterioration in her recall accelerated in the last six months.It was starting to wear on him. He was losing his wife right in front of his eyes. Marys poor performance on an in-depth memory test revealed that that she was so advanced that should be in an assisted living facility. This frightened both the Hollers and their children.

Peter Holler sought out stem cell dementia treatment. He felt it was his wifes only option. Peter, no stranger to stem cells, had undergone a stem cell treatment by Dr. Zannos Grekos for his failing heart in 2008. He had experienced great success. Even my lung function improved dramatically, he recalls. Going back to the same group that he had trusted, he made arrangements to get the love of his life treated.

A track record of several successfully treated patients with dementia already existed. So the doctors knew exactly what to do. Heading the team is Dr. Hector Rosario, an interventional cardiologist and head of the stem cell program in the Dominican Republic. Dr Roberto Fernandez DeCastro head of the catheterization lab assisted in the procedure. Dr Grekos, Chief Scientific Officer for the company was present as well. Its very exciting to be able to have such a positive impact on a disease process that otherwise has such a grim prognosis, Grekos explained. The Dementia Treatmentprotocol used to treat Mrs. Holler had been developed specifically for patients with dementia by Dr Zannos Grekos.

Below arebefore(top) and after (bottom) angiogramsof Mrs. Hollers left internal carotid injections:

Stem cells collected from Marys bone marrow are subjected to an activation and concentration process. The stem cells were then injected into her cerebral circulation. Look at the difference, Dr Rosario exclaimed while pointing to the before and after pictures of the brain circulation. The increase in blood vessel flow was astonishing.Since only adult stem cells from the patient are used, the political, ethical, and medical issues are avoided and there is no risk of rejection.

Were able to normalize a patients neuro-cognitive (brain function) testing in 6 months after the stem cell dementia treatment said Zannos Grekos MD, commenting on the success of patients having received adult stem cell dementia treatment to reverse the effects of dementia. Peter Holler agrees, Not only does she not repeat questions any more, but she is also remembering things that she had forgotten. Its a godsend.

Dementia is a loss of brain function that occurs with age and certain diseases. Most types of dementia are nonreversible (degenerative).It affects memory, thinking, language, judgment, and behavior. Alzheimers disease is a common type of dementia.Dementia also can be due to many small strokes or poor circulation. This is called vascular dementia. Many dementias have a vascular component; these are referred to as mixed dementias. Stem cells are especially effective in treating these types of dementias.

Dr. Zannos Grekos colleagues in the world medical field are currently employing adult stem cell therapy and coordinating its application for patients who have exhausted all other traditional therapy options. His presentation at the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies conference supports efforts by a global community of doctors that are striving to incorporate adult stem cell therapy into mainstream medicine.

Regenocyteis an international corporation located in Bonita Springs, Florida. Dedicated to leading the world in providing Adult Stem Cell therapies, Regenocyteutilizes the most effective and safest technologies and medical procedures in order to improve the lives of its patients. A video of Dr. Zannos Grekos presentation at the 16th Annual World Congress on Anti-Aging Medicine & Regenerative Biomedical Technologies is available for viewing on the companys website. Additional information on adult stem cell therapy as well as patient video experiences can be found at http://www.regenocyte.comor call (866) 216-5710.

To learn more about dementia please click here

For more information on Doctor Grekos, MD please click here

More here:
Stem Cell Treatment for Dementia | Stem Cell Doctors ...

Read More...

Animal Longevity and Scale

January 25th, 2019 12:45 am

A useful line of analysis is to consider the effect of scale changes for creatures which aresimilar in shape and only differ in scale. As the scale of an animal increases the body weight and volume increase with the cubeof scale. The volume of blood flow required to feed that bulk also increases with the cube of scale. The cross sectional area of the arteries and the veins required to carry that blood flow only increases with the square of scale. There are other area-volume relationships which impose limitations on creatures. Some of those area-volume constraints, including the above one, are:

Thus to compensate for the body needs which increase with the cube of scale but the areas increase with only the square of scale the average blood flow velocity must increase linearly with scale. Blood flow velocity is driven by pressure differences. The pressuredifference must be great enough to carrying the blood flow to the top of the creature and great enough to overcome the resistance in the arteries and veins to the flow. The pressure required to pump blood from the heart to the top of the creature is proportional to scale.The pressure difference required to overcome the resistance to flow through the arteries intothe capillaries and back again through the veins is more difficult to characterize in terms of scale.The greater cross sectional area reduces the resistance but the long length increases resistance. The net result of these two scale influences seems to be that the pressure difference required to drive the blood through the bulk of the creature is inversely proportional to scale. The pressure difference imposed would be the maximum of the two required pressure differences.

Shown below are the typical blood pressures for creatures of different scales.

The linear regression of the logarithm of pressure on the logarithm of height yields the following result:

The linear regression of the logarithm of pressure on thelogarithm of weight yields:

If blood pressure were proportional to scale then the coefficient for *log(Height) would be 1.0 and for *log(Weight) would be 0.333 since weight to proportional to the cube of scale.The regression coefficients are not close to the theoretical values but they are of the proper order of magnitude for accepting blood pressure as beingproportional to scale.

The volume of the heart of a creature is proportional to the cube of scale. The volumeof the blood to be moved is also proportional to the cube of scale. From the previous analysis the flow velocity is proportional to scale. Therefore the time required to evacuatethe heart's volume is proportional to scale. This means that the heartbeat rate is inverselyproportional to scale. The following table gives the heart rates for a number of creatures.

A regression of the logarithm of heart rate on the logarithm of weight yields the followingequation:

If heart rate were exactly inversely proportion to scale the coefficient for *log(weight)would be -0.333. This is because scale is proportional to the cube root of weight.The coefficient of -0.2 indicates that the heart rate is given an equation of the form

One salient hypothesis is that the animal heart is good for a fixed number of beats. This hypothesis can be tested by comparing the product of average heart rate and longevity for different animals. Because the heart rate is in beats per minute and longevity is in years thenumber of heart beats per lifetime is about 526 thousand times the value of the product. Thedata for a selection of animals are:

Although the lack of dependence is clear visually the confirmation in terms of regression analysis is:

The t-ratio for the slope coefficient is an insignificant 0.15, confirming that there is no dependence of lifetime heartbeats on the scale of animal size.

If a heart is good for just a fixed number of beats, say one billion, then heart longevity is this fixed quota of beats divided by the heart rate. From the above equation for heart rate,lifespan (limited by heart function) would be proportional to scale raised to the 0.6 power.

The data for testing this deduction are:

For the data in the above table, admittedly very rough and sparse, the regression of the logarithm of the lifespan on thelogarithm of weight gives

Thus the net effect of scale on animal longevity is positive. Taking into account that weight is proportional to the cube of the linear scale of an animal the above equation in terms of scale would be

This says that if an animal is built on a 10 percent larger scale it will have a 6 percentlonger lifespan.

Go here to read the rest:
Animal Longevity and Scale

Read More...

Genetics | The Institute for Creation Research

January 25th, 2019 12:43 am

For over 150 years, Darwins hypothesis that all species share a common ancestor has dominated the creation-evolution debate. Surprisingly, when Darwin wrote his seminal work, he had no direct evidence for these genealogical relationships. Now, with online databases full of DNA-sequence information from thousands of species, the direct testing of Darwins hypothesis has finally commenced. More...

Authentic speciation is a process whereby organisms diversify within the boundaries of their gene pools, and this can result in variants with specific ecological adaptability. While it was once thought that this process was strictly facilitated by DNA sequence variability, Darwin's classic example of speciation in finches now includes a surprisingly strong epigenetic component as well. More...

One of the rapidly expanding and exciting research fields in molecular biology is the area of epigenetics. In the study of epigenetic modifications, scientists analyze DNA that has been modified in such a way that its chemistry is changed, but not the actual base pairs that make up the genetic code of the sequence. Its like a separate control code and system imposed upon and within the standard code of DNA sequence.

Because epigenetic modifications in the genome are related to gene expression, researchers have been using highly advanced technologies for comparing these differences in humans and chimps for regions of the genome that they both have in common. More... More...

Living things develop partly according to genetic instructions encoded on their DNA. The study of inheritance has widened the paradigms from genes to genomes, and now recent research indicates that critical biological information is carried from one generation to the next in systems additional to DNA, called epigenetic factors.

So, where did this information come from? More...

Genes could be thought of as brick molds, used to construct materials for building the physical structures of living organisms. They carry the codes to help make proteins, which then make up different cells that are combined together to form mega-structures called tissues.

New research has shed more light on how genes are used by cells to build the different tissues needed by complex living creatures. More...

Indiana University researchers discovered that certain genes used in developing horned beetle larvae are re-used later to make horns in their adult stage. The studys authors called the genes co-opted, indicating their belief that evolution decided to give them a secondary use. The authors suggestion that gene co-opting offers a possible explanation for the development of novel traits comes up short, however. More...

One of the past arguments for evidence of biological evolution in the genome has been the concept of pseudogenes. These DNA sequences were once thought to be the defunct remnants of genes, representing nothing but genomic fossils in the genomes of plants and animals. More...

Amazingly, scientists documented the activity of 2,082 distinct pseudogenes in the human genome whose aberrant levels of activity were directly associated with cancer-specific pathologies. More...

Proteins do most of the required metabolic tasks within each of the trillions of cells in the human body. However, only about four percent of human DNA contains coded instructions that specify proteins.

So what is the purpose of the remaining 96 or so percent? More...

A research team recently characterized a group of genes in humans and other mammals that not only defies evolutionary models but vindicates the Bibles prediction of the uniqueness of created kinds with distinct genetic features. More...

Read more from the original source:
Genetics | The Institute for Creation Research

Read More...

Page 884«..1020..883884885886..890900..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick